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INTRODUCTION 
 Hematopoietic stem cell transplantation (HSCT) has evolved from an 
experimental option to standard therapy in many congenital and acquired hematopoietic 
disorders as well as malignancies. More than 30,000 allogeneic HSCTs are done every 
year, with a likely increase by 5-10% each year.1 Rates of transplantation continue to 
increase for all indications.2 Graft versus Host Disease (GVHD) is a major complication 
of HSCT. It is defined as the aggregation of clinical and pathological manifestations in a 
recipient of allogeneic stem cells or bone marrow transplantation in which specific 
immunological as well as nonspecific phenomena lead to characteristic features. Based on 
the time of presentation, it has been traditionally classified as acute and chronic GVHD.3 
Acute GVHD appears within 100 days of the transplant and chronic GVHD after 100 
days.4 The usual presentation of acute GVHD is a maculopapular rash.5 The spectrum of 
chronic GVHD includes lichenoid and sclerodermoid forms, the latter containing lichen 
sclerosus, morphea, panniculitis and fasciitis.6 
 Incidence of GVHD can be upto 80%, depending on human leukocyte antigen 
(HLA) mismatch, age, gender and conditioning regimen.4 Despite success in decreasing 
the incidence of acute GVHD (eg. via prophylaxis with immunosuppressive medications), 
the incidence of chronic GVHD has increased from approximately 40% in 1990 to 80% 
today.7,8  
Risk factors for GVHD include: 
1. Characteristics of the donor and recipient: HLA disparity, unrelated HLA-matched 
donor (mismatched minor histocompatibility antigens), female donor to male 
recipient, older age of donor or recipient and prior acute GVHD 
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2. Characteristics of the transplantation protocol: more intense preparative regimen 
(myeloablative vs. reduced-intensity conditioning regimens), source and dose of 
hematopoietic stem cells- G-CSF-mobilized peripheral blood rich in CD34+ cells, 
unmodified (T-cell-replete) graft; less aggressive administration of prophylactic 
immunosuppressive agents (to prevent GVHD)  
3. Later interventions to incite a graft-versus-malignancy effect, namely withdrawal 
of immunosuppressive drugs and donor T lymphocyte infusions.9  
 The incidence of GVHD in Western literature varies widely. Studies in Japan and 
Taiwan have shown a lower incidence, attributed to lesser genetic diversity. We 
undertook a study to determine the incidence of graft versus host disease, describe the 
various clinical presentations of muco-cutaneous GVHD, establish the clinico-
pathological correlation of acute cutaneous GVHD and analyze the risk factors for GVHD 
in a tertiary referral center in India. 
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AIMS AND OBJECTIVES 
 
1. To estimate the incidence of muco-cutaneous GVHD in a tertiary referral center in 
south India.  
2. To describe the various clinical presentations of muco-cutaneous GVHD. 
3. To establish the clinico-pathological correlation of acute cutaneous GVHD.  
4. To analyze the risk factors for GVHD. 
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REVIEW OF LITERATURE 
Introduction: 
 GVHD is a major complication of HSCT. GVHD was described very early in the 
history of HSCT and is a donor-derived immunological response against recipient tissue 
antigens.1 HSCT has been integrated into treatment algorithms as first line therapy in 
aplastic anemia, after 1st complete remission in high risk acute leukemias, and as rescue 
therapy in non-responders, relapsed or aggressive leukemias and lymphomas.1  
Types of HSCT: 
 The types of transplants (based on donor type) can be autologous, when patient’s 
own cells are used for transplant; syngeneic, when the cells of a twin are used; allogeneic, 
when cells from another person are used as stem cell source, either from the same family 
or from an unrelated donor. 
 Depending on whether the HLA, that is, the major histocompatibility complex 
(MHC), is matched or not, the donor can be an HLA identical sibling, or other family 
member, a non-HLA identical family member, or an unrelated donor, either HLA 
matched or mismatched.3 The perfect HLA match or the 10/10 allele match is a sibling 
donor with identical alleles of the HLA-A, -B, -C, DRB1 and DQB1 loci. The total 
number of mismatched alleles, locus of the mismatched allele and resolution of the 
mismatch determine the effect of outcome.10 
 HSCT is of different types based on the site and mode of harvest; bone marrow 
transplantation, in which stem cells are collected from bone marrow by repetitive 
puncture of the bone marrow; peripheral blood stem cell transplantation, in which stem 
cells are collected from peripheral blood with a cell separator after mobilization of stem 
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cells with G-CSF to the peripheral blood; and cord blood transplantation, in which stem 
cells are collected from umbilical cord blood and placenta of the newborn immediately 
after delivery.3 Peripheral blood stem cell transplants (PBSCT) are being performed 
increasingly due to the ease of collection, faster engraftment kinetics, less immediate 
morbidity associated with stem-cell procurement, similar clinical outcome and 
economical advantages.11 The advantages of using cord blood as stem cell source are 
absence of risk to the donor, immediate availability of cells, low risk of transmitting 
infections and a low risk of GVHD.12  
Sequence of events: 
 The sequence of events in HSCT includes pre-transplant conditioning, and the 
transplant procedure itself.1 The conditioning regimen is the pre-transplantation treatment 
with chemo-radiotherapy to reduce or eradicate the tumor burden and immunosuppress 
the host in order to allow engraftment of the transplant, and creates space for the graft.1,3 
It can be either myeloablative conditioning (traditional regimen), in which primary targets 
are the elimination of the tumor cells as well as the induction of a state of 
immunosuppression in the host, or a reduced intensity conditioning, in which the primary 
target is to induce a state of immunosuppression in the host; elimination of the recipient 
stem cells as well as of residual tumor cells is mainly performed by immunocompetent 
donor cells.3 Nonmyeloablative conditioning reduces the damage to the host’s tissues and 
can maintain a transient or prolonged state of hematopoietic-cell chimerism, which is an 
indication of immunologic tolerance.13 Hematopoietic chimerism refers to all marrow 
cells of the recipient being of donor origin, whereas all the other tissues are native to the 
host.14 
6 
 
The transplant procedure consists of infusing the stem cells harvested from bone 
marrow, peripheral blood or cord blood intravenously.1 After infusion of stem cells, they 
home to the marrow and reconstitute the immunologic and hematopoietic system of the 
recipient.14  
Engraftment: 
As the graft begins to function, during neutrophil recovery, a wave of cytokine 
function without concomitant T cell mediated attack, results in fever, rash and fluid 
retention, in the form of pulmonary edema, referred to as “engraftment syndrome” or 
“capillary leak syndrome”. It occurs in the 1st 1 to 2 weeks of the transplant and may be 
associated with increased mortality, especially from pulmonary failure. Prompt 
improvement with corticosteroids is characteristic.15  
Graft versus host disease 
 GVHD is a clinical syndrome, initially described as “runt disease” in mice.16 The 
first published report was probably in 1960, when transplants were used to treat nuclear 
accident survivors.15 GVHD is caused by the recognition of major and/or minor 
histocompatibility antigen differences by alloreactive T-lymphocytes in the stem cell 
graft.17 Cutaneous GVHD is one of the most common complications of allogeneic 
HSCT.18 Clinically significant disease occurs in about 50% patients,14,19 ranging between 
35-75%.20 It can occur in about 8% patients undergoing autologous transplantation.  
Etiology:  
The original pre-requisites of GVHD as described by Billingham, in 1966, stated 
that the transplanted graft must contain immunologically competent cells, the recipient 
must express tissue antigens that are not present in the transplant donor and the recipient 
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must be incapable of rejecting the transplanted cells.21 These tenets were revised in 2006, 
to include the effector cells migrating to the target tissues.22 
Histocompatibility: 
Class II HLA molecules (DR, DQ and DP) are presented by CD4+ T cells, thus 
helping them to recognize foreign antigens. In antigen presenting cells (APCs), the 
dimerization of DR1 molecule may induce co-stimulatory molecule expression.5  Minor 
histocompatibility antigens (miH) are peptides recognized by donor T cells that are 
derived from intracellular proteins and presented by MHC molecules.23 After the 
presentation of miH by the MHC to the donor T cells, the non-self peptide bound to the 
MHC molecules trigger the CD8+ T cell in case of MHC class I and CD4+ T cell in case of 
MHC class II thereby inducing GVHD.5 The minor histocompatibility antigens HY and 
HA-3 are targets for GVHD.24  
Pathophysiology: 
The current concept explaining the mechanism of GVHD is that phenomena 
namely alloreactivity, autoimmunity and immunodeficiency occur in differing intensities, 
alloreactivity mainly involved in the acute stage and autoimmunity in the chronic stage, 
depicted in Figure 1.3 
Acute GVHD: 
Two principles govern the pathophysiology of acute GVHD, typical inflammatory 
mechanisms are exaggerated in the foreign environment of host they are infused into and 
recipient’s tissues that are damaged by underlying disease, conditioning regimen and 
prior infections stimulate the donor cells.24 There are three sequential stages for the 
development of GVHD, depicted in Figure 2.3 The first two stages form the afferent 
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phase and the last stage, the effector phase. The afferent phase starts even before the 
infusion of the graft and is at the time of conditioning where the patient receives total 
body irradiation (TBI) or high dose chemotherapy as part of a myeloablative regimen and 
to suppress the host’s ability to reject the graft. Damaged tissues express inflammatory 
cytokines like IL-1, -6, TNF-α, GM-CSF and IFN-γ which upregulate adhesion molecules 
and enhance MHC antigens.5  Intestinal mucosa is mainly damaged by the conditioning, 
leading to translocation of lipopolysaccharides (LPS) from the lumen into the circulation, 
which causes cytokine expression.25 
The second phase involves donor T cells recognizing foreign host antigens, 
getting activated and stimulated. Host APCs stimulate T cells via cytokines like IL-1 and 
IL-2 and are essential for this phase of GVHD. Adhesion molecules involved in T cell 
adhesion and activation include E-selectin, VLA-4, LFA-1, ICAM-1, PECAM-1 and 
VECAM-1.5 There are genetically distinct epithelial cells in the basal layer which are 
confined to the rete ridges in the skin and rete-like prominences in the dorsal tongue 
known as selectively targeted apoptotic rete (STAR) cells, which preferentially express 
adhesion molecules like CD106 and a specific cytoskeletal protein termed cytokeratin 
15.26 
In the effector phase of GVHD, there is direct and indirect damage to the host 
cells. A predominance of T helper type 1 (Th1) cells leads to activation of cytotoxic T 
lymphocytes (CTLs), and the presence of a cytokine storm, including IL-1, -2, -8, TNF-α 
and IFN-γ. CTLs and natural killer (NK) cells mediate cytotoxicity via TNF-α, perforin-
granzyme B and Fas-Fas ligand.5 LPS and other stimulatory molecules from the intestinal 
mucosa trigger immune cells through secondary signals. Complex interactions between 
dendritic cells and immune effectors play a major role in the development of GVHD.25  
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Chronic GVHD: 
Macrophages mainly produce TGFβ in the skin, which is critical in 
Sclerodermatous (Scl) GVHD.27 In early fibrosing disease there is a Th1 environment 
with cytokines like IFNγ, IL-2 and -18,27 chemokines like CXL9/Mig, CXCL10/IP-10 
and CXCL11/I-TAC and growth factors like PDGF, FGF1, EGF and nerve growth factor-
β.28 Later, a T helper type 2 (Th2) profile predominates with CCL17, CTGF and VEGF.28 
Hypotheses on pathogenesis include thymic damage by acute GVHD leading to failure to 
delete nascent T cells which recognize antigens, TGFβ, B cell and antibody mediated 
mechanisms and dysfunctional T-regulatory cells.29 
Risk factors:  
Acute GVHD: 
The risk factors of acute GVHD include HLA and miH antigen mismatch, high 
dose chemotherapy or TBI as conditioning, presence of intestinal anaerobic bacterial 
microflora, advanced age, gender mismatch, especially female multiparous donor with 
male recipient, multiple transfusions, underlying primary disease especially chronic 
myeloid leukemia (CML), positive cytomegalovirus serology, splenectomised recipient, 
dose of immunosuppressive prophylactic regimen5 and number of T cells in the graft.30 
Peripheral blood rather than bone marrow transplant is a risk factor for chronic, not acute 
GVHD.5 The main risk factor is histoincompatibility. H-Y antigens are expressed by male 
recipients on their Y chromosome, and are recognized as foreign by female donor cells.15 
In a HLA matched sibling donor transplant, the risk of grade II to IV GVHD was upto 
50%, but increased to 60% with disparity of one antigen, 75% with two and 90% with 
three antigens.14 A multivariate analysis revealed that incompatibility with respect to 
HLA-A and HLA-C alleles between the donor and host were independent strong risk 
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factors for the development of severe acute GVHD.31 A single mismatch between either 
HLA-A, -B, -C or -DR locus correlated with increased incidence of severe acute GVHD; 
whereas HLA-A and/or -B resulted in increased chronic GVHD.32 
A high degree of donor chimerism is associated by the development of GVHD, 
probably due to reduced-intensity conditioning regimens. Other controversial risk factors 
include exposure to herpes viruses, CD34+ cell dose, certain HLA alleles and ABO 
incompatibility.15 Granulocyte colony-stimulating factor (G-CSF) was associated with 
increased risk of grade II acute GVHD in HLA matched sibling transplants despite 
prophylaxis with cyclosporine and methotrexate.33 There is conflicting data on the use of 
stimulating factors like G-CSF and GM-CSF and the incidence of GVHD.34 
Studies done to assess risk factors in acute GVHD are summarized in Table 1. 
Table 1.  Studies assessing risk factors of acute GVHD: 
Author Ref. Risk factor 
Vargas-Diez E et al35 CML 
TBI 
HLA disparity 
Nash RA et al36 Gender mismatch, especially with a parous donor 
Myeloablative conditioning 
Disease status 
Hahn T et al37 CML 
Older age 
 
Chronic GVHD: 
The most important risk factors for chronic GVHD are prior acute GVHD, 
prophylactic regimen for acute GVHD, age of the recipient being more than 20 years, T 
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cell replete graft, second marrow infusion, transfusion of non-irradiated donor buffy coat, 
female donor (especially parous) for male host and a history of herpes infection.38,8 
Controversial risk factors include patient characteristics like CMV seropositivity or 
reactivation and splenectomy, donor characteristics like ethnic difference between donor 
and host and the presence of corticosteroids or lack of Methotrexate in the acute GVHD 
prophylaxis regimen and high CD34+ count (PBSCT).8 A positive random skin biopsy, in 
the absence of symptoms or a history of previous acute GVHD predicts the risk of 
chronic GVHD to be three times.34  
The risk of chronic GVHD has increased as more patients with increasing age and 
co-morbidities are taken for HSCT, the eligibility criteria for the same has been 
expanded, there is increased HLA disparity, prolonged survival due to better prophylactic 
drugs for acute GVHD and treatment of other early complications, and increased use of 
peripheral blood stem cells rather than bone marrow for infusion.3,7 T cell depletion, cord 
blood transplantation and Antithymocyte globulin (ATG) decrease the incidence of acute 
GVHD, but don’t prevent chronic GVHD.7,9 
Incidence: 
Incidence of GVHD can be upto 80%, depending on HLA mismatch, age, gender 
and treatment regimen,4 occurs in two-third of HLA identical sibling transplants and one-
fifth of them are severe.1 The incidence of acute GVHD in thalassemia was 26.9% in a 
single center in Italy.39  The incidence of GVHD in children is less than that of adults.40 
The reported incidences of acute and chronic GVHD are depicted in Tables 2 and 3 
respectively. 
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Table 2. Reported incidence of acute GVHD: 
Acute GVHD 
Author Ref. Year Incidence 
Mauduit G et al41 1988 50-80% 
Aractingi S et al42 
Fimiani M et al38 
1998 
2003 
Mean 35% 
6-90% 
Goker H et al5 2001 HLA matched 
50-90% 
Ferrara JLM at al24 2009 HLA matched 
40% 
Ringden O et al43 1995 HLA matched sibling 
11% 
Matched unrelated donor 
15% 
Tabbara IA et al44 2002 HLA Matched 
20-50% 
HLA mismatched sibling or 
matched unrelated donor 
50-80% 
 
Table 3. Reported incidence of chronic GVHD : 
Chronic GVHD 
Author (Reference) Year Incidence 
Matsuoka LY et al45 1981 Upto 25% 
Mauduit G et al41 1988 30% 
Penas PF et al46 2010 60-80% 
Fujii H et al47 1992 32% No difference if prior acute GVHD 
Fimiani M et al38 2003 30-50% With prior acute GVHD 
70% 
Sullivan KM et al48 1991 HLA matched 
33% 
Mismatched 
49% 
Matched 
unrelated donor 
64% 
Ringden O et al43 1995 HLA matched sibling 
22% 
Matched unrelated donor 
29% 
Ilhan O et al49 1997 HLA matched 
30-55% 
Mismatched 
70-90% 
Horwitz ME et al34 2006 1 antigen HLA-non-identical unrelated donor 
Upto 80% 
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In the study done in Japan, the differences compared to Western data were 
attributed to histocompatibility antigens having a lesser degree of genetic diversity.47 A 
study in Taiwan had a reduced prevalence of grade II to IV acute GVHD, again attributed 
to lower levels of genetic diversity and to isolation rooms which had laminar airflow.50  
Clinical features: 
The diagnosis of GVHD is clinical; no reliable laboratory tests can confirm or 
refute the diagnosis.15 
Hyperacute GVHD: 
Hyperacute GVHD, a fulminant, rare form of disease, is seen in the 1st week after 
transplant with fever, erythroderma, hepatitis and vascular leakage.5 It is also known as 
early mismatch GVHD.3 It was found in 27% of grade II to IV acute GVHD; can occur 
even before neutrophil engraftment and is associated with a reduced response to standard 
therapy, with increased non-relapse mortality, in matched unrelated donor or mismatched 
related donor transplants.51  
Acute GVHD: 
Acute GVHD usually occurs between two and six weeks after transplant,5 most 
commonly between day 7 and 21,38,42 median onset being day 19.52 With high intensity 
conditioning, it occurs between 14 and 35 days, with GVHD prophylaxis of Cyclosporine 
and Methotrexate, median onset is 21 to 25 days after transplant.15 The peak incidence is 
around day 30 after myeloablative conditioning.3  
Acute GVHD is rather organ specific, the lymphocytes enter the target tissue as 
they possess the required combination of homing and chemokine receptors to engage the 
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endothelium.22 The target organs of acute GVHD are skin, liver, gut, lung and lymphoid 
tissue.46 The skin, gut and liver are affected in decreasing order of frequency.40 
Extracutaneous acute GVHD is almost always accompanied by skin disease.14 
Skin: 
The expression of acute GVHD in the skin is called acute cutaneous graft versus 
host reaction.53 The skin can be the sole target of acute GVHD.3 The most common and 
earliest clinical presentation of acute GVHD is a pruritic maculopapular rash involving 
the ears, nape of neck, shoulders, palms and soles in the early stage, resembling a 
sunburn,5 spreading to the cheeks and upper trunk,30  which can progress to erythroderma 
and even epidermal necrolysis.5 Bullae can appear with a positive Nikolskiy sign.3 The 
symmetrical morbilliform rash usually begins acrally and becomes disseminated. The 
characteristic features include acral erythema, violaceous discoloration of the ears and 
folliculocentric erythema that blanches with small macules and papules.3 The rash can be 
asymptomatic or painful.15 A rash usually precedes gastrointestinal and liver 
involvement,54 and is associated with fever and pancytopenia.38 Acute GVHD can also 
present as a scarlatiniform rash or a rash similar to varicella infection,42 ichthyosiform 
eruptions46 or acute psoriasiform cutaneous GVHD.55 It can rarely present with discrete, 
erythematous to violaceous follicular papules56 with central hyperkeratosis.57 Oral, 
conjunctival and vaginal lesions which don’t heal with hematological recovery may 
represent mucosal GVHD.15 Manifestations attributed to oral acute GVHD include 
punctate or generalized mucosal erythema, mucosal erosions, desquamation, ulceration, 
mucoceles, xerostomia and white striae similar to lichen planus. Most commonly, the 
tongue, labial and buccal mucosa are involved.52   
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A retrospective study done on 15 patients with stage IV acute GVHD revealed 
that the patterns of evolution could be a slow progression from an erythematous rash to 
vesiculobullous lesions, where numerous vesicles were seen or flaccid bullae on frictional 
areas were noted or quick progression from an erythematous rash to extensive denudation 
of skin. Median interval between onset of a rash and appearance of vesicles was 19 days. 
Mucosal involvement in the form of oral erosions was most common.18  
Differential diagnosis: 
Patients who have more than 60% body surface area involvement with an 
erythematous rash have a high prevalence of GVHD.58 The differential diagnosis for 
acute cutaneous GVHD includes drug rash, viral exanthem and the eruption of 
lymphocyte recovery. There can be a considerable overlap between clinical and 
histological features of these conditions.9 Eruption of lymphocyte recovery (ELR) also 
presents as macules and papules between day 14 and 21. This time corresponds to the 
earliest re-appearance of lymphocytes in the peripheral circulation after marrow ablation. 
Impending immunologic reconstitution can be predicted by identifying this eruption.53 
Cause of this eruption may be due to unopposed reactivity to autoantigens or due to 
homing of returning lymphocytes in the skin. On an average, ELR is seen earlier than 
GVHD.59 Involvement of palms and soles in characteristic of GVHD, but can also occur 
due to the conditioning regimen, more commonly with Busulphan, manifesting as painful, 
blistering acral erythema, resembling a second degree burn. Severe acute GVHD doesn’t 
usually involve the conjunctiva, hence helping to differentiate it from toxic epidermal 
necrolysis.15 
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Liver: 
The liver is the second most common organ to be involved in acute GVHD, 
manifesting with conjugated hyperbilirubinemia and elevation of alkaline phosphatase in 
the early stages.5 Transaminase abnormalities are less common.15  
Gut: 
The gastrointestinal (GI) tract is the third most commonly involved organ in 
GVHD and the most severe and difficult to treat. Any site can be involved, presentation is 
with diarrhea, abdominal cramps, nausea, vomiting, distension, ileus, bleeding,5 anorexia, 
malabsorption and ascites.42 The colon is more commonly involved than the ileum.15 
Acute upper GI GVHD in older patients presents with anorexia, nausea, vomiting, 
dyspepsia and food intolerance, and is more responsive to treatment.5  
Other sites: 
Presence of acute lung GVHD is still controversial.15 GVHD in lymph nodes leads 
to diminution of germinal centers. GVHD may cause thrombocytopenia.5 
Grading: 
An overall GVHD grade is the composite score of the skin, liver and gut stage. 
The histological grade is different from the clinical grade. Staging of acute GVHD 
adapted from consensus conference, depending on the extent of organ involvement is 
represented in Table 4.60-62  
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Table 4. Staging of acute GVHD adapted from the consensus conference: 
Stage Skin Liver Gut 
1 Rash<25% of skin 
(body surface area 
according to the 
rule of nines) 
Bilirubin 2-3mg/dl Diarrhea>500ml/day 
or persistent nausea 
with biopsy 
confirming GVHD 
2 Rash 25-50% Bilirubin 3-4mg/dl Diarrhea 
>1000ml/day 
3 Rash >50% of skin Bilirubin 6-15mg/dl Diarrhea>1500ml/day 
4 Generalized 
erythroderma with 
bullae 
Bilirubin>15mg/dl Severe abdominal 
pain ± ileus  
 
Criteria for grading are given as minimum degree of organ involvement for each grade, 
shown in Table 5.  
Table 5. Grading of acute GVHD adapted from the consensus conference: 
Grade Skin Liver Gut 
I Stage 1-2 None None 
II Stage 3 or Stage 1 or Stage 1 
III - Stage 2-3 or Stage 2-4 
IV Stage 4 or  Stage 4 - 
 
The consensus grading and International Bone Marrow Transplant Registry 
(IBMTR) GVHD severity index are in use now.15 Revised criteria were proposed for 
grading acute GVHD to categorize clinical management, as there was considerable 
disagreement in assigning acute GVHD grades by the original criteria by independent 
reviewers. This new criteria has limited prognostic utility and is shown in Table 6.63 
 
 
18 
 
Table 6. Revised criteria for grading acute GVHD: 
Grade Features 
I No convincing evidence of GVHD at any time; all abnormalities in skin, 
liver and gut fully accountable by processes other than GVHD; no 
immunoprophylaxis given except for originally planned prophylaxis. 
II Rash characteristic of GVHD in clinical presentation and time of onset 
(with or without visceral GVHD) or biopsy proven visceral GVHD 
without rash; improvement without need for treatment or progressive 
improvement within 2-3 weeks after starting treatment; no need for 
secondary treatment. 
III Clinical presentation as described for grade II but without progressive 
improvement after starting treatment, or requiring multiple cycles of 
treatment or extended hospitalization, but without GVHD as a clinically 
significant contributing cause of death. 
IV Clinical presentation as described in grade II but with GVHD as a 
clinically significant contributing cause of death. 
 
Traditionally GVHD occurring after 100 days was considered chronic, but now 
chronic GVHD is characterized by clinical features rather than temporal onset.64 Features 
of acute GVHD can occur after day 100 and clinical features of chronic GVHD even 
shortly after transplant,3 and has been recorded as early as 40 days after transplant.42 
Hence, these criteria should be used only as a guide.65 Subcategories include classic 
acute, persistent, recurrent or late onset acute, classic chronic and overlap syndrome. 
Persistent, recurrent or late onset acute GVHD usually occurs on withdrawal of 
immunosuppression.9,66 Patients with late acute GVHD had gut and liver involvement 
more often and skin involvement less often compared to patients with acute GVHD.67 
Patients with overlap syndrome have more extensive disease.68 
Categories of acute and chronic GVHD, from the National Institute of Health 
(NIH) consensus are depicted in Table 7.66 
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Table 7. Categories of acute and chronic GVHD, NIH consensus: 
Category Time of symptoms after HSCT 
Presence of acute 
GVHD features 
Presence of 
chronic GVHD 
features 
Acute GVHD 
Classic acute 
GVHD 
 
≤100 days 
 
Yes 
 
No 
Persistent, recurrent 
or late-onset acute 
GVHD 
>100 days Yes No 
Chronic GVHD 
Classic chronic 
GVHD 
 
No time limit 
 
No 
 
Yes 
 
Overlap syndrome No time limit Yes Yes 
 
Chronic GVHD: 
Chronic GVHD is a heterogeneous chronic syndrome,3 that has emerged as the 
most troublesome complication of transplantation, as more patients survive the early post-
transplant period due to improvements in HLA typing for unrelated transplants, better 
immunosuppressive prophylactic regimens, reduced intensity conditioning regimens, 
improved supportive care,64 older recipient age and use of peripheral blood cells as graft 
source.8 It is a pleiomorphic syndrome usually occurring around four months after the 
transplant,69 between 3 and 24 months, resembling autoimmune diseases, and is 
associated with a reduced risk of recurrent malignancy.8 Cutaneous GVHD can no longer 
be treated as a limited anti-epithelial process, but is also anti-endothelial and potentially 
anti-multicellular, resulting in cellular cytotoxicity and tissue damage.1 Chronic GVHD 
can occur in three ways, in 20-30% patients, it presents as progression of acute GVHD 
known as the progressive type, in another 30-40% as recurrence after treatment of acute 
GVHD known as quiescent or interrupted type and in 35% without prior acute GVHD 
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known as the de novo type.42,8 The de novo type has the least and the progressive type the 
highest mortality.14 It can be triggered by UV radiation, trauma or infections like zoster or 
Borreliosis, or may appear spontaneously.42 Cutaneous manifestations are seen in almost 
all patients with chronic GVHD,14 in upto 80% of HLA identical transplants receiving 
Methotrexate prophylaxis with oral involvement in upto 72%.8  
The extended clinical and histological spectrum of chronic GVHD includes 
lichenoid and sclerodermoid forms, the latter containing lichen sclerosus, morphea, 
panniculitis and fasciitis.70 In chronic GVHD, the incidence of lichenoid GVHD, lichen 
planus-like, was found to be 9%, sclerodermoid GVHD was 38%, lichen sclerosus-like 
was 50% and eosinophilic fasciitis was 6%.9 Sclerodermatous GVHD (Scl GVHD) 
comprises 10-15% of chronic GVHD.27 
Early clinical features of chronic GVHD may be subtle, and include xerosis, 
keratosis pilaris-like lesions, ichthyosis, papulosquamous lesions, psoriasiform, pityriasis 
rosea-like lesions and annular lesions similar to annular psoriasis, subacute cutaneous 
lupus erythematosus or superficial erythema annulare centrifugum.3 Hallmark features of 
chronic GVHD are dry, scaling skin1 and poikiloderma.3 Pigmentary changes include a 
bronzed hyperpigmentation,38 leopard-like pigmentation,9 vitiligo-like lesions,38 
leukoderma and leukotrichia.71 Lesions resembling lupus erythematosus,34 
dermatomyositis,72 a generalized ageing process,38 reactive isomorphism,73 exfoliative 
dermatitis74 and erythema multiforme-like targetoid lesions have been described.75 
Guttate, shiny indurated lesions may be seen on the trunk.34 Other features of chronic 
cutaneous GVHD include bullae or ulcers over sclerodermoid lesions, eczema craquele, 
nodular fibromas, cutaneous focal mucinosis,9 eruptive angiomas,76 hand and foot 
eczema-like vesiculation, scaling or acral keratoses, erythema annulare centrifugum,65 
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bullous pemphigoid, epidermolysis bullosa acquisita, histiocytic cytophagic panniculitis 
and pyoderma gangrenosum.38 A newly described type of chronic cutaneous GVHD is 
termed eczematoid GVHD, which is a severe, usually erythrodermic eruption associated 
with a poor prognosis that requires substantial immunosuppression.77 A maculopapular 
rash can occur in chronic GVHD, after reducing immunosuppressants or transfusing with 
donor lymphocyte infusions.65 Planar xanthoma due to cholestasis secondary to chronic 
GVHD has been described.78 
Scarring and non-scarring alopecia of scalp, axillary and pubic hair have been 
noted. Nail changes can occur early, and include periungual erythema, fragility, atrophy, 
onycholysis, thickening, longitudinal striations, dystrophy, pterygium, white patches38 
and periungual telangiectasias. Nail involvement was found in half the patients with 
chronic cutaneous GVHD in Turkey and was associated with longer duration of disease.79 
Changes in sweating may be present. Many patients, upto 80%, can have oral and genital 
epithelium involvement, including dryness, atrophy, hypertrophy, erosions and white 
plaques.3 Oral pain was a common complaint in patients with chronic GVHD.52 Oral 
involvement is seen in 72% patients with chronic GVHD,8 mucosal involvement in upto 
80% patients.42 Mouth and eyes are the most common mucosal surfaces to be involved.38 
A Sjögren like syndrome is almost always seen.42 Deep erythema is followed by reticulate 
white lichen planus-like mucosal lesions and hyperkeratotic plaques. Lesions may persist 
for many years, with a 4 times greater risk of squamous cell carcinoma than the general 
population.38 Lingual papillae may be short, absent or even elongated, geographical 
tongue may be seen.65 Of the oral manifestations, lichen planus-like features were the 
most distinctive, with the highest positive predictive value.52 The incidence of ocular 
GVHD was found to be 5.5%, the most common presentation being keratoconjunctivitis 
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sicca.80 On an average of 10 months post-transplant, vaginal symptoms, most commonly 
dryness, itching and tenderness develop, leading to dyspareunia.81 
Lichen planus-like GVHD: 
Lichenoid lesions were thought to be the early form of chronic cutaneous GVHD, 
but can occur before, with or after sclerodermoid change.9 Classical lichen planus-like 
lesions are violaceous lichenoid papules and plaques seen over the dorsae of hands, 
forearms and trunk.3,9 Common sites of involvement are the palms and soles, but groin, 
ears and peri-orbital region can be involved.38 Perifollicular papules and follicular 
hyperkeratosis may be noted.9 Folliculotropism may be a feature3 and rarely, it may be 
dermatomal (kertinocyte antigenicity being altered by varicella zoster infection) or follow 
Blaschko’s lines (cellular mosaicism causing a clone of cells to have different 
histocompatibility antigens).38 Photosensitive eruptions similar to subacute cutaneous 
lupus erythematosus or dermatomyositis may represent lichenoid GVHD.82 
Morphea-like GVHD: 
 Plaques of dermal sclerosis similar to morphea characterize the sclerodermoid 
type of chronic GVHD, which eventually progress to generalized scleroderma.3 These 
lesions appear as circumscribed, firm, hyperpigmented or skin colored plaques that are 
indurated on palpation and favor the lower trunk,9 major skin folds and proximal 
extremities.38 A predilection for the limbs was recently described.83 The skin appears 
‘hidebound’ with ‘pipestem legs’.65 Other features include dermal nodules, atrophic white 
plaques and dimpled, hyperpigmented, tethered skin.83  
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Lichen sclerosus-like GVHD: 
Lichen sclerosus-like features can be seen in genital or extragenital locations and 
comprise 50% of sclerodermatous patients. The neck and upper to mid-trunk, especially 
sites of recently removed central venous catheters are preferred sites. Hypopigmented 
plaques are seen with wrinkling, scaling and follicular plugging. The mean time of onset 
of these lesions was day 300, as an initial manifestation of sclerodermoid GVHD.84 The 
link between lichenoid and sclerodermoid GVHD may be the lichen sclerosus lesions,9 or 
these lesions may be a distinct subtype of chronic GVHD.85 
Eosinophilic fasciitis-like GVHD: 
Eosinophilic fasciitis-like features can be seen and represent a deep from of 
sclerodermoid GVHD. It can be seen in 58% patients, mean onset being day 700. 
Strenuous physical activity was found to precipitate this feature in many patients. 
Peripheral eosinophilia can be seen in upto 60% patients.84 The limbs, excluding the 
hands and feet are most commonly involved.  Acute pain and edema are followed by the 
appearance of induration known as “pseudocellulite”. “Groove sign” refers to a 
depression along the course of a vein, between muscle groups, or both.9 Deep fascial 
involvement is characterized by peau d’orange appearance. A positive prayer sign, where 
wrist dorsiflexion is acutely limited, may be seen.65  
Signs and symptoms of chronic GVHD are modified from the NIH consensus in 
Table866.  
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Table 8. Signs and symptoms of chronic GVHD, NIH consensus: 
Organ or 
site Diagnostic criteria 
Distinctive 
criteria Other features 
Common 
(seen with 
both acute 
and chronic 
GVHD)
Skin Poikiloderma (atrophy 
and pigmentary 
changes) 
Lichen planus-like 
features  
Sclerotic features 
Morphea-like features 
Lichen sclerosus-like 
features 
Depigmentation Sweat impairment 
Ichthyosis 
Keratosis pilaris 
Hypopigmentation 
Hyperpigmentation 
Erythema
Maculopapula
r rash 
Pruritus 
 
Mouth Lichen-type features
Hyperkeratotic 
plaques Restriction of 
mouth opening        
from sclerosis 
Xerostomia
Mucocele 
Mucosal atrophy 
Pseudomembranes 
Ulcers  
 Gingivitis
Mucositis 
Erythema 
Pain 
 
Genitalia Lichen planus-like 
features  
Vaginal scarring or 
stenosis 
Erosions 
Fissuring  
Ulceration 
  
Nails  Dystrophy
Longitudinal 
ridging, splitting, 
brittle nails or loss 
of nails 
Onycholysis 
Pterygium unguis
  
Scalp and 
body hair 
 New onset 
scarring or non-
scarring alopecia 
Scaling, 
papulosquamous 
lesions 
Thinning scalp hair, 
typically patchy, 
coarse, or dull (not 
explained by 
endocrine or other 
causes) 
Premature gray hair 
 
Eyes  New onset dry, 
gritty, or painful 
eyes 
Cicatricial 
conjunctivitis 
Keratoconjunctivit
is sicca  
Confluent areas of 
punctuate 
keratopathy
Photophobia
Periorbital 
hyperpigmentation 
Blepharitis 
 
GI tract Esophageal web 
Strictures or stenosis 
in the upper to mid-
third of the esophagus
 Exocrine pancreatic 
insufficiency 
Anorexia
Nausea 
Vomiting 
Diarrhea
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Weight loss
Failure to 
thrive (infants 
and children) 
Total 
bilirubin, 
alkaline 
phosphatase>2
x upper limit 
of normal
Lung Biopsy showing 
bronchiolitits 
obliterans 
Bronchiolitis 
obliterans 
diagnosed by 
pulmonary 
function testing or 
radiology 
 
 Bronchiolitis 
obliterans-
organizing 
pneumonia 
Muscles, 
fascia, 
joints 
Fasciitis 
Joint stiffness or 
contractures secondary 
to sclerosis 
Myositis or 
polymyositis 
Edema 
Muscle cramps 
Arthralgia or arthritis 
 
Hematop
oietic and 
immune 
  Thrombocytopenia 
Eosinophilia 
Lymphopenia 
Hypo- or 
hypergammaglobulin
emia 
Autoantibodies 
(AIHA and ITP) 
 
Other   Pericardial or pleural 
effusions 
Ascites 
Peripheral 
neuropathy 
Nephrotic syndrome 
Myasthenia gravis 
Cardiac conduction 
abnormality or 
cardiomyopathy
 
 
If any of the manifestations included in the diagnostic criteria are present, the 
presence of chronic GVHD can be established without further testing or evidence of other 
organ involvement. Distinctive criteria are manifestations not ordinarily found in acute 
GVHD, but are not enough to establish the diagnosis of chronic GVHD without further 
testing. Other features can be a part of chronic GVHD, once the diagnosis is established. 
Common muco-cutaneous features can be seen in both acute and chronic GVHD. 
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Diagnosis of chronic GVHD can be made if there is at least one diagnostic manifestation 
or at least one distinctive manifestation with confirmation of diagnosis by biopsy or 
laboratory testing or imaging in the same or another organ.66 Organ scoring of chronic 
GVHD, from the NIH consensus is summarized in Table 9.9,66  
Table 9. Organ scoring of chronic GVHD, NIH consensus: 
 Score 1 Score 2 Score 3 
Skin <18% BSA, no sclerotic 
features 
19-50% BSA or superficial 
sclerosis 
>50% BSA or deep 
sclerosis or impaired 
mobility, ulceration or 
severe pruritus 
Mouth Mild signs/symptoms not 
limiting oral intake 
Moderate signs/symptoms 
with partial limitation of 
oral intake
Severe signs/symptoms 
with major limitation of 
oral intake 
Eyes Mild dry eye symptoms 
or asymptomatic but 
signs of 
keratoconjunctivitis 
sicca 
Moderate dry eye 
symptoms partially 
affecting ADL, no visual 
impairment 
Severe dry eye 
symptoms affecting 
ADL or unable to work 
or loss of vision 
Gut Symptoms without 
significant weight loss 
Symptoms with weight loss 
of 5-15% 
Symptoms with weight 
loss>15%, requiring 
nutritional 
supplementation or 
esophageal dilatation
Liver Bilirubin, alkaline 
phosphatase or 
transaminases <2x of 
normal upper limit
All 2-5x of normal upper 
limit or bilirubin >3mg/dl 
All >5x of upper 
normal limit 
Lungs Mild symptoms (SOB 
after 1 flight of steps), 
FEV1 60-79% or LFS 2 
Moderate symptoms (SOB 
after walking on flat 
ground), FEV1 40-59% or 
LFS 6-9
Severe symptoms 
(SOB at rest), FEV1 
≤39% or LFS 10-12 
Joint/fascia Mild tightness of arms or 
legs, mildly decreased 
ROM and not affecting 
ADL 
Tightness of arms or legs, 
joint contractures, erythema 
due to fasciitis, moderately 
decreased ROM or mild to 
moderate limitation of ADL
Contractures with 
significantly decreased 
ROM and significant 
limitation of ADL 
Genital 
tract 
Mild signs/symptoms, no 
effect on coitus/minimal 
discomfort on 
examination 
Moderate signs/symptoms 
and mild 
dyspareunia/discomfort on 
examination 
Advanced signs 
(strictures, labial fusion 
or severe ulceration) 
and severe pain with 
coitus/ inability to 
insert vaginal speculum
Global 
assessment 
Mild 
1-2 organs, except the 
lung, with a maximum 
organ score of 1 each
Moderate
≥1 site with organ score 2 
or ≥3 sites with an organ 
score of 1 or lung score of 1
Severe 
Any organ score of 3 or 
lung score of 2 
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ADL=Activities of daily living; BSA=body surface area; FEV1=forced expiratory volume 
in 1 s; LFS=lung function score (includes FEV1 and diffusion capacity of the lung for 
CO); ROM=range of motion; SOB=shortness of breath. 
Cutaneous response to therapy can be graded using the NIH scale or the Hopkins 
scale.86 Chronic GVHD was classified as limited or extensive, in Table 10.87,34  
Table 10. Classification of chronic GVHD: 
Limited chronic GVHD 
Either or both: 
1. Localized skin involvement 
2. Hepatic dysfunction due to chronic GVHD 
Extensive chronic GVHD 
Either: 
1. Generalized skin involvement, or 
2. Localized skin involvement &/ or hepatic dysfunction due to chronic GVHD 
Plus: 
      3a. Liver histology showing chronic aggressive hepatitis, bridging necrosis or 
cirrhosis, or 
      b. Involvement of eye (Schirmer test with<5mm wetting), or  
      c. Involvement of minor salivary glands or oral mucosa demonstrated on labial 
biopsy, or 
      d. Involvement of any other target organ  
 
A revised classification was described in 2003, with features of clinical limited 
and clinical extensive chronic GVHD, depicted in Table 11.8 
Table 11. Revised classification of chronic GVHD: 
Clinical limited: 
1. Oral abnormalities consistent with chronic GVHD, a positive skin or lip biopsy, 
and no other manifestations of chronic GVHD 
2. Mild liver test abnormalities (alkaline phosphatase <2 x upper limit of normal, 
AST or ALT <3 x upper limit of normal, and total bilirubin <1.6) with positive 
skin or lip biopsy, and no other manifestations of chronic GVHD 
3. Less than 6 papulosquamous plaques, macular-papular or lichenoid rash involving 
<20% of BSA, dyspigmentation involving <20% BSA, or erythema involving 
<50% BSA, positive skin biopsy, and no other manifestations of chronic GVHD 
4. Ocular sicca (Schirmer’s test <5 mm with no more than minimal ocular 
symptoms), positive skin or lip biopsy, and no other manifestations of chronic 
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GVHD 
5. Vaginal or vulvar abnormalities with positive biopsy, and no other manifestations 
of chronic GVHD 
Clinical extensive: 
1. Involvement of 2 or more organs with symptoms or signs of chronic GVHD, with 
biopsy documentation of chronic GVHD in any organ 
2. Karnofsky or Lansky Clinical Performance scores <60%, >15% weight loss, and 
recurrent infections not due to other causes, with biopsy documentation of chronic 
GVHD in any organ 
3. Skin involvement more extensive than defined for clinical limited chronic GVHD, 
confirmed by biopsy 
4. Scleroderma or morphea 
5. Onycholysis or onychodystrophy thought to represent chronic GVHD, with 
documentation of chronic GVHD in any organ 
6. Decreased range of motion in wrist or ankle extension due to fasciitis caused by 
chronic GVHD 
7. Contractures thought to represent chronic GVHD 
8. Bronchiolitis obliterans not due to other causes 
9. Positive liver biopsy; or abnormal liver function tests not due to other causes with 
alkaline phosphatase >2 x upper limit of normal, AST or ALT >3 x upper limit of 
normal, or total bilirubin >1.6, and documentation of chronic GVHD in any organ 
10. Positive upper or lower GI biopsy 
11. Fasciitis or serositis thought to represent chronic GVHD and not due to other 
causes 
 
Differential diagnosis:  
 There are no absolute clinical characteristics that can declare a rash to be due to a 
drug rather than GVHD.88,69 Other differentials are viral infections, chronic 
radiodermatitis and autoimmune diseases like systemic lupus erythematosus, scleroderma, 
Sjögren’s syndrome, rheumatoid arthritis, dermatomyositis and polymyositis. Oral 
candidiasis can mimic lichenoid GVHD.34 In Scl GVHD, Raynaud’s phenomenon and 
acrosclerosis are usually absent.38,42  
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Histopathology: 
Acute GVHD: 
The findings of a skin biopsy include an upper dermal infiltration by T cells, 
exocytosis into the epidermis and dyskeratotic epidermal cells.59 Biopsy findings are 
characterized by the degree of keratinocyte damage and categorization is into 4 grades as 
in Table 12.53,89  
Table 12. Histopathological grading of acute GVHD: 
Histopathological 
grade Features 
1 Vacuolization of the basal keratinocytes 
2 Dyskeratotic keratinocytes as well 
3 Focal clefting of the basal layer 
4 Separation of the epidermis from dermis totally 
 
Apoptosis is a typical feature of GVHD. The dermo-epidermal junction is most 
severely affected.15 Satellite cell necrosis is the term used to describe dyskeratotic 
keratinocytes in close proximity to epidermal lymphocytes.90 To establish a diagnosis of 
GVHD, at least grade 2 changes should be present.59 Grade 1 changes can be considered 
adequate in GVHD occurring after day 35.91 No single feature on the biopsy can be 
considered pathognomonic.9,92 The follicular epithelium can be an early target in acute 
cutaneous GVHD.56 Histopathology of stage IV acute GVHD was classified as a 
necrolysis pattern, in which full epidermal necrosis seemed to originate in the upper 
layers, a GVHD pattern, in which necrosis of basal layers were noted at the edge of the 
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lesion representing vacuolar interface changes and a mixed necrolysis and GVHD 
pattern.18  
The use of skin biopsy to confirm the diagnosis of acute cutaneous graft-versus-
host disease is still controversial as delaying treatment of GVHD till a biopsy confirms 
the diagnosis could lead to rapid progression of the disease while on the other hand is the 
risk of sepsis with the use of immunosuppression.58 The cause of a new onset rash in a 
transplant patient is best determined by close examination and follow-up of clinical 
features without a biopsy, biopsies seldom alter the treatment.93 Treatment of suspected 
acute GVHD depends on clinical suspicion and not biopsy findings as they are mostly 
non-specific. A skin biopsy helps to consolidate the diagnosis with liver function tests and 
intestinal biopsy, gives insight into evolution to chronic GVHD and allows comparison 
with future skin biopsies.58 Serial biopsies establish a baseline for interpretation of 
subsequent biopsies.94 The diagnostic yield of a skin biopsy can be increased by careful 
selection of the site from an established perifollicular lesion by an experienced 
dermatologist.9 Clinically involved skin can show unremarkable histology whereas 
normal skin can show features of GHVD.30 Liver or intestine biopsy can unambiguously 
confirm the diagnosis of GVHD, unlike in the skin.93  
In a retrospective study it was found that a skin biopsy performed before 21 days 
of the transplant had no value in ruling out acute GVHD and epidermal lymphocytes 
should be present to diagnose acute GVHD.89 Another retrospective study determining 
the frequency and use of skin biopsy within 30 days of transplant revealed that biopsy 
features didn’t correlate with clinical severity of the rash, which finally influenced the 
decision to treat the patient; hence the practice of performing a routine biopsy can be 
abandoned without comprising the care of the transplanted patient.30 If the sensitivity and 
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specificity of the skin biopsy specimen is very high, the best clinical outcome is found 
when a skin biopsy is performed, while simultaneously initiating treatment, then 
treatment is revised according to results of the biopsy. Where the prevalence of GVHD is 
>30%, it is best to treat GVHD without a skin biopsy, whereas where the prevalence is 
<30%, a skin biopsy would best guide treatment.58 The risk versus benefit ratio favors the 
performance of a biopsy of a suspected GVHD rash as this potentially life threatening 
complication needs aggressive immunosuppression.9,95  
Differential diagnosis:   
A skin biopsy, by suggesting another diagnosis may help to substantiate the 
clinical diagnosis, but can’t prove the diagnosis of GVHD by itself.15 Infectious processes 
can be suggested by a neutrophilic infiltrate, viral inclusions or special stains, while a 
drug rash can be suggested by abundance of eosinophils and chemotherapy induced 
changes by eccrine gland necrosis. Histologic changes may appear later than the clinical 
cutaneous eruption.89 Histology of drug eruptions caused by drugs with a sulfhydryl 
group is similar to GVHD with liquefactive necrosis.96  There are no reliable 
differentiating histological features between drug hypersensitivity and GVHD, hence it is 
better to presume GVHD and follow up the patient.69 Chemotherapy artifact areas should 
be avoided while trying to establish a diagnosis of GVHD; they are defined by the loss of 
orderly progression of cuboidal basal cells to flat squamous cells, irregular nuclear 
contour and occasional dyskeratotic cells.53 Acral erythema due to chemotherapy reveals 
vacuolar degeneration of the basal layer, necrotic keratinocytes, spongiosis, papillary 
dermal edema and a mild perivascular lympho-histiocytic infiltrate. Another histological 
differential includes subacute radiation dermatitis.54 Biopsy findings of ELR include 
upper dermal infiltration of CD3+4+ lymphocytes, vascular dilatation, lymphocytic 
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exocytosis, intercellular edema and rarely, dyskeratotic keratinocytes.53 Satellite cell 
necrosis can also be present in an ELR.59  
Chronic GVHD: 
Histopathological criteria for chronic muco-cutaneous GVHD, with clinical, 
laboratory and radiology yield four diagnostic categories namely, no GVHD, possible 
GVHD, consistent with GVHD and definite GVHD. The NIH consensus criteria are 
shown in Table13.92 
Table13. NIH consensus criteria for chronic GVHD: 
Organ or 
system 
Minimal criteria for 
active GVHD 
Specific criteria for chronic GVHD 
Skin, any 
stage 
Apoptosis in the epidermal 
basal layer or lower 
malpighian layer or outer 
root sheath of hair follicle 
or acrosyringium ± 
lichenoid inflammation ± 
vacuolar change ± 
lymphocytic satellitosis 
 
 
Skin, lichen 
planus-like 
 Combination of epidermal 
orthokeratosis, hypergranulosis and 
acanthosis with lichenoid changes ± 
syringitis of eccrine units ± 
panniculitis 
 
Skin sclerotic  Collagenous deposition with 
thickening throughout the papillary 
dermis, or pan-dermal collagenosis ± 
panniculitis 
 
Skin morpheic  Clinically focal or localized lesions 
predominated by sclerosis in the lower 
reticular dermis or along the dermal-
hypodermal border ± epidermal and 
appendageal involvement 
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Skin fasciitis  Fibrous thickening of fascial septa with 
adjacent inflammation ± panniculitis 
Liver Global assessment of 
dysmorphic or destroyed 
small bile ducts ± 
cholestasis, lobular &/or 
portal inflammation 
Ductopenia, portal fibrosis, and 
chronic cholestasis reflect chronicity 
but are not specific for chronic GVHD 
Gastrointestin
al 
Variable apoptotic criteria 
(≥1/piece) in crypts 
Destruction of glands, ulceration, or 
submucosal fibrosis reflects long-
standing disease but are not specific for 
chronic GVHD 
Oral mucosa 
and 
conjunctiva 
Lymphocytic infiltration of 
mucosa with variable 
apoptosis 
 
Minor 
salivary or 
lacrimal gland 
 Infiltration and damaged intralobular 
ducts, fibroplasias in periductal stroma, 
and inflammation with destruction of 
acinar tissue 
Lung  Obliterative bronchiolitis: dense 
eosinophilic scarring beneath the 
respiratory epithelium, resulting in 
complete fibrous obliteration or some 
degree of luminal narrowing  
 
GVHD Prophylaxis: 
The main approach for prevention of GVHD is to avoid the risk factors if 
possible. Strategies to prevent GVHD include matching of histocompatibility antigens of 
the host and donor, in vivo immunosuppression as prophylaxis, protective environment, 
gut decontamination, total lymphoid irradiation, thymic transplant and in vitro treatment 
of donor stem cells, like ATG with complement, monoclonal anti-T cell antibodies, E-
rosette depletion, lectin separation, elutriation and immunoadsorbent column.52 Without 
prophylaxis, incidence of GVHD can approach 100%.5 An ideal prophylactic regimen 
would eliminate acute and chronic GVHD, allow immunologic recovery effectively and 
maintain graft-versus-tumor effect.97 Calcineurin inhibitors, with or without Methotrexate 
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are used as immunosuppressive drugs. Manipulation of the graft by depleting the T cells 
has lower organ toxicity than immunosuppressants but is associated with increased risk of 
relapse or rejection, delayed immune reconstitution, decreased functional recovery of T 
lymphocytes and impaired recovery of diversity of the T cell repertoire.3 Standard GVHD 
prophylactic regimen target the second phase of the pathophysiology of GVHD, 
calcineurin inhibitors inhibit T cell proliferation and IL-2 expression, whereas 
Methotrexate targets T cells that are rapidly dividing.98 
A recent meta-analysis done to evaluate various prophylactic regimens for acute 
GVHD concluded that the combination of Cyclosporine and Methotrexate was superior to 
Cyclosporine and that the combination of Methotrexate and Tacrolimus was superior to 
Methotrexate and Cyclosporine with respect to lowering acute GVHD.99 
In randomized trials aimed at chronic GVHD prevention, there was no difference 
in incidence of chronic GVHD irrespective of the dose or duration of Cyclosporine, 6 
months versus 24 months,7 or with addition of immunoglobulin irrespective of dose.8 
Combination drug prophylaxis is usually given immediately post-transplant which 
is slowly tapered after 100 days and stopped around 180 days. Tacrolimus was found to 
be as effective as Cyclosporine but less toxic, but patients on Cyclosporine had a better 
survival.5  
New agents for GVHD prophylaxis include Rapamycin, Trimetrexate, 
Deoxyspergualin, Chloroquine, PG27, CTLA4Ig, Glutamic acid-lysine-alanine-tyrosine 
(GLAT), Neuraminidase, Fludarabine and 2 deoxy-chloroadenosine.5 Cytokine based 
approaches include antithymocyte globulin, anti-TNFα targeted strategies (Infliximab, 
Etanercept) and anti-IL-2 receptor antibody (Daclizumab).3  
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Treatment of GVHD:   
GVHD is still considered the “Achilles heel” of HSCT.97  
Acute GVHD: 
The standard of treatment for acute GVHD is corticosteroids, the mechanism of 
action probably due to lympholytic action. Methylprednisolone 2mg/kg/day is the starting 
dose.5 If after 3 days, the disease worsens, after 7 days remains the same or after 14 days 
doesn’t respond fully; second line therapy should be initiated.46 Other therapies include 
Thalidomide,3 Hydroxychloroquine, Methotrexate, Acitretin, Cyclophosphamide,9 
monoclonal antibodies for treatment of acute GVHD, including Zomazyme, B-C7, IL-1 
receptor antagonist, CD11a antibody5 and Rituximab.9 Other skin directed therapies 
include phototherapy and photochemotherapy; UVA1 (340-400nm) is especially effective 
in sclerodermoid GVHD.9 Supportive care is as important as targeted therapy.1 
Therapeutics in steroid resistant acute GVHD are summarized in Table 14.100 
Table 14. Therapeutics in steroid resistant acute GVHD: 
Polyclonal antibody Antithymocyte globulin 
Monoclonal antibody OKT3, Visilizumab, ABX-CBL, Daclizumab, Inolimomab, 
Basiliximab, Alemtuzumab, Alefacept 
Biologic toxin-conjugate Denileukin diftitox 
TNFα blocker Infliximab, Etanercept 
Chemotherapy Mycophenolate, Pentostatin, calcineurin inhibitors, 
Sirolimus 
Phototherapy PUVA, photochemotherapy 
Cellular therapy Mesenchymal stem cells 
Topical / directed 
therapy 
Oral Beclomethasone or Budesonide for intestinal GVHD; 
intra-arterial steroid or Methotrexate infusion 
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Chronic GVHD: 
The principles of management of chronic GVHD include patient education,8 
immunosuppression, topical therapy and antibiotic prophylaxis for infection.101 Ongoing 
supportive care, adequate hydration, maintenance of nutrition and careful follow up are 
essential.7 Strict vigilance against complications of the disease and treatment are 
indicated, including infections, hypertension, hyperglycemia, osteoporosis, renal 
dysfunction and hyperlipidemia.102 Drugs used to treat acute GVHD are also useful to 
treat chronic GVHD.103 At diagnosis, Prednisolone 1mg/kg/day with Cyclosporine 
10mg/kg/day is given. Tapering is by 25% per week after two weeks, if the disease 
doesn’t worsen till 1mg/kg prednisolone on alternate days. After steroid tapering, 
Cyclosporine is tapered by 25% per week, alternating with Prednisolone. Most patients 
show response to therapy in three months.101 Most patients require prolonged steroid 
therapy; only less than half are able to discontinue immunosuppression by two years.102 If 
there is failure to improve after at least two months of treatment, or worsening after a 
month of standard therapy, including steroids and Cyclosporine, it is referred to as steroid 
refractory chronic GVHD.8 There is no standard salvage therapy for these patients, in 
small phase II trials and case series, various agents have been tested, and have response 
rates of 20-80%.102 
For local therapy of chronic GVHD, topical steroids have been the standard 
treatment. Topical Tacrolimus ointment has been used as a safe alternative with transient 
burning being the only major side effect, and serum levels being below the systemic 
therapeutic range for graft rejection prevention. The control of erythema and pruritus was 
evident rather rapidly.104  
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Prognosis: 
Acute GVHD: 
Prognosis of acute GVHD correlates with the initial stage at presentation. Long 
term survival of patients with acute GVHD grade 0-I is about 50% and grade IV is upto 
11%.100 Acute GVHD is the reason for death in 40 to 50% patients with moderate to 
severe disease.46,52 Severity of acute GVHD is the most important prognostic factor 
predicting the outcome of the transplant.30 Mild to moderate acute GVHD (grade I or II, 
A or B) has less mortality, but is a risk factor for development of subsequent chronic 
GVHD, whereas severe GVHD (grade III or IV, C or D) has a grave prognosis with a 
mortality rate as high as 100%.15 Patients who survive grade IV acute GVHD develop 
severe chronic GVHD less often.105 The onset pattern of late acute GVHD symptoms and 
not presence of features of acute GVHD may be important in prognosis.68 The most 
predictive parameter for progression of GVHD is the peak clinical stage.106 
Chronic GVHD: 
The presence of chronic GVHD is considered the main determinant of late 
infectious complications.38 It is the main cause of non-relapse mortality in transplant 
survivors and has a major impact on quality of life and functional status of these 
patients.107 It is associated with 30-50% risk of mortality.8 Prognostication in chronic 
GVHD includes timely diagnosis; appropriate management and close follow up. Non-
relapse mortality in patients with chronic GVHD was related to extensive skin 
involvement, progressive onset of chronic GVHD from acute GVHD and 
thrombocytopenia.101 A scheme for grading chronic GVHD was suggested based on the 
prognostic factor score and absolute number of risk factors, which can be used to 
individualize treatment of patients.101  GVHD is the cause of death in 12 to 20% patients. 
Death in these patients is usually due to infection, cachexia or liver failure.42 Most deaths 
are due to infection.101 Ten year survival rate is 80% in patients with mild chronic GVHD 
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and 5% in those with severe chronic GVHD.34 Skin involvement in sclerodermoid GVHD 
indicates better disease-free survival due to decreased relapse rate, but extracutaneous 
involvement increases mortality rate.83 Many reports suggest that lichenoid GVHD 
histology is a poor prognostic factor,108,109 whereas sclerodermatous histology is not, but 
Akpek et al110 found that histology of cutaneous chronic GVHD didn’t have any 
prognostic value.  A retrospective study revealed that the three year survival of patients 
with late acute GVHD was worse than overlap syndrome and chronic GVHD.67  Despite 
treatment, the outcome of a third of patients with chronic GVHD remains the same.101 
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MATERIALS AND METHODS 
Study design: 
 Single-centre, prospective, longitudinal cohort study 
Study setting: 
 This study was conducted in Christian Medical College, an 1800 bedded tertiary 
care institution in Vellore, Tamil Nadu, after approval by the institutional review board. 
The patients were recruited from the Haematology out-patient department and wards. The 
first bone marrow transplant in this centre was done in 1986. Bone marrow transplants 
have been performed regularly and successfully since 1988. Peripheral blood stem cell 
transplants began in 1998. The first cord blood transplant was done in 2001 and the first 
unrelated donor transplant in 2008. 
Study subjects: 
 The patient population eligible to be in the study was all patients in the 
Hematology department undergoing a stem cell transplant. 
Inclusion criteria: 
 All patients undergoing allogeneic hematopoietic stem cell transplantation and 
consented to participate in the study. 
Exclusion criteria: 
 Patients who were not willing for the study. 
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Study period: 
 The study period was from March 2009 to July 2010; patients were recruited from 
March, 2009 to April, 2010 and followed up till July, 2010. 
Methodology: 
 All patients undergoing hematopoietic stem cell transplantation were screened and 
recruited into the study prior to the transplant procedure. At the time of registration into 
the study, a written informed consent was taken from the patient (Annexure 1), or the 
parent or legally acceptable guardian if the patient was a minor. A children’s assent form 
(Annexure 2) was used for minors who were literate. All details of history, clinical 
examination and relevant investigations were recorded in a proforma (Annexure 3). 
 All patients were examined by the principal investigator (PI) prior to the 
transplant to enable post transplant changes to be recognized clearly. Demographic data 
was collected from the records, as were the pre-transplant diagnosis, donor related 
information, stem cell source and conditioning regimen. Any skin lesion present prior to 
the transplant was recorded. A detailed dermatological evaluation was done including the 
skin, nail and mucosal surfaces. The day the stem cells were infused was termed ‘Day 0’. 
During the transplant period the patient was admitted in the Bone Marrow Transplant 
Unit (BMTU) and followed up daily. Engraftment was considered as absolute neutrophil 
count of ≥500/mm3 (0.5 x 109/L) achieved for three consecutive laboratory values tested 
on different days and platelets of ≥20 x 109/L achieved for three consecutive laboratory 
values, with no platelet transfusions in the previous seven days. If the patient developed 
any skin rash, this was evaluated by the PI. The presence and extent of skin rash and oral 
mucosal involvement was clinically assessed, photographs were taken and biopsies 
performed where indicated, to help confirm the diagnosis, with the patient’s consent. A 
4mm punch biopsy specimen was taken, which was fixed in skin fixative solution; 
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histopathological examination by light microscopy with haematoxylin and eosin staining 
was done by the department of Pathology. The patient was also monitored for any 
occurrence of diarrhea to evaluate for gut GVHD and abnormalities in liver function tests 
to evaluate for liver GVHD. Once the patient stabilized and was discharged, follow up 
was periodically thereafter, every week or month, or if any muco-cutaneous symptoms 
appeared. Any cutaneous clinical feature consistent with GVHD which appeared before 
100 days post-transplant was considered as acute GVHD, and with onset after 100 days 
was considered chronic GVHD. Acute GVHD was graded clinically as per the1994 
Consensus Conference, summarized in Table 4.62,60,61 A biopsy was done for any new 
onset rash, unless the patient declined consent for the same, or the patient had 
characteristic white reticulate oral mucosal plaques occurring after 100 days post-
transplant clinically suggestive of lichenoid GVHD. If chronic GVHD occurred as a 
continuation of acute GVHD, it was classified as progressive, if it occurred after complete 
resolution of acute GVHD, as quiescent and if it occurred without prior acute GVHD as 
de novo. Chronic GVHD was further classified as limited or extensive, as in Table 
10.87,34 Histopathological grading was done as in Table 1253,89 and the NIH consensus 
criteria for chronic GVHD was used, as shown in Table 13.92 Patients with significant 
gastrointestinal symptoms were subjected to a biopsy to confirm the clinical diagnosis of 
GVHD. Liver biopsy was not done; the diagnosis of liver GVHD was purely clinical and 
depended on liver function testing. Routine investigations, including total count, 
differential count and liver function tests were done as per the standard protocol of 
transplant in the Haematology department, daily till the patients engrafted, then on 
alternate days for a week, then twice a week till the patient was discharged, thereafter at 
follow up, once a month or once in 3 months as required, or earlier if there were any 
abnormal results.  
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Research committee approval: 
 The Institutional Review Board approved of this study (Annexure 4). 
Statistical analysis: 
The sample size was 92. Sample size was calculated based on the prevalence of 
GVHD found to be 35.7% in thalassemia patients in India, a precision of 10% with 
confidence intervals of 95%. 
N= 4 x p x q = 4 x 36 x 64 =92 
d2                        102 
where, p= prevalence of GVHD, q= p-1 and d is the difference. 
All statistical analysis was performed using SPSS 11.0 for windows (SPSS Inc, 
Chicago, IL).  Frequency and percentages were used to describe the distribution of 
categorical variables, median and ranges were used to describe continuous variable that 
were not normally distributed. Chi-square test was used to assess the association between 
categorical variables. Continuous variables were compared using t-test.  Weighted kappa 
statistic was used to assess agreement between clinical and histopathological grades of 
GVHD; squared weights were employed. The agreement was analyzed using R 2.8.0 
(“irr” library). Logistic regression was employed to estimate the adjusted odds ratios as 
measure of risk for GVHD against potential risk factors. Kaplan Meier plots were used to 
display the distribution of times to engraftment and GVHD. 
 A p-value of less than 0.05 was considered statistically significant.  
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RESULTS 
Demographic profile:  
Of a total of 105 patients who underwent allogeneic hematopoietic stem cell 
transplantation during the study period, 102 consecutive patients who consented were 
recruited into the study. 
The age and sex distribution of the recipients is represented in Table 15. 
Table 15. Age and sex distribution of the transplant recipients: 
Age group in 
years Males (%) Females (%) 
<10 19 (59.4) 13 (40.6) 
11-20 13 (68.4) 6 (31.6) 
21-30 12 (75) 4 (25) 
31-40 12 (75) 4 (25) 
41-50 8 (61.5) 5 (38.5) 
51-60 3 (50) 3 (50) 
 
Socio-demographic profile of the patients and donors is summarized in Table 16. 
Table 16. Socio-demographic profile: 
Variable Descriptive statistics 
Patient age* 20.5 (1-58) 
Children (<15 years)* 44 (43.1) 
Patient gender: 
     Males# 
 
67 (65.7) 
     Females# 35 (34.3) 
Marital status: 
Married# 
 
40 (39.2) 
Urban residence# 90 (88.2) 
Donor age* 26 (2-60) 
Donor gender: 
     Males# 
 
57 (55.9) 
     Females# 45 (44.1) 
*Median (range) #Frequency (%) 
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Table 17. Primary diagnosis and donor relation: 
Diagnosis 
Relationship of the donor 
Sibling Parent Unrelated 
Thalassemia 24 (88.9%) 3 (11.1%) - 
AML 19 (67.9%) 2 (7.1%) 7 (25%) 
ALL 8 (72.7%) - 3 (27.3%) 
Aplastic anemia 16 (88.9%) 2 (11.1%) - 
Myelodysplastic syndrome 3 (50%) - 3 (50%) 
Biphenotypic leukemia 1 (50%) - 1 (50%) 
Kostmann syndrome 1 (100%) - - 
Fanconi’s anemia 2 (100%) - - 
Pure red cell aplasia 1 (100%) - - 
Juvenile myelomonocytic leukemia 1 (100%) - - 
Paroxysmal nocturnal hemoglobinuria - - 1 (100%) 
CML 2 (100%) - - 
Wiskott Aldrich Syndrome 1 (100%) - - 
Severe combined immunodeficiency - 1 (100%) - 
 
Unrelated donor transplants were done for AML, ALL, myelodysplastic 
syndrome, biphenotypic leukemia and paroxysmal nocturnal hemoglobinuria. 
HLA typing: 
 High resolution typing was done for unrelated transplants, 10/10 antigens 
being HLA matched, whereas low resolution typing was done for related transplants, 
identical HLA type being 6/6. Most of the related transplants were HLA matched whereas 
the unrelated transplants mostly had a single antigen mismatched. HLA typing is 
summarized in Table 18. 
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The most common source of hematopoietic stem cells was peripheral blood in 71 
patients (69.6%), followed by bone marrow in 30 patients (29.4%). 
Distribution of patients according to primary diagnosis and source of hematopoietic stem 
cells is depicted in Table 19. 
Table 19. Primary diagnosis and source of stem cells: 
Diagnosis 
Source of hematopoietic stem cells 
BMT PBSCT CBT 
Thalassemia 25 (92.6%) 2 (7.4%) - 
AML - 28 (100%) - 
ALL - 11 (100%) - 
Aplastic anemia - 18 (100%) - 
Myelodysplastic syndrome 1 (16.7%) 5 (83.3%) - 
Biphenotypic leukemia - 2 (100%) - 
Kostmann syndrome 1 (100%) - - 
Fanconi’s anemia 1 (50%) 1 (50%) - 
Pure red cell aplasia 1 (100%) - - 
Juvenile myelomonocytic 
leukemia 
- 1 (100%) - 
Paroxysmal nocturnal 
hemoglobinuria 
- 1 (100%) - 
CML - 2 (100%) - 
Wiskott Aldrich Syndrome - - 1 (100%) 
Severe combined 
immunodeficiency 
1 (100%) - - 
 
Peripheral blood has become the most common source of stem cells, although 
bone marrow transplants are still being done, mostly for the thalassemia patients. Cord 
blood transplantation was performed in a single patient with Wiskott Aldrich Syndrome. 
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Follow up period: 
 The median follow up was 164 days, range 8-515 days. The overall survival of 
patients was plotted as a Kaplan Meier curve in Figure 8. 
Figure 8. Overall survival: 
  
Engraftment: 
 The median time to engraftment of neutrophils was 16 days (range, 9-57), 
depicted in Figure 9 and time to engraftment of platelets was 17 days (range, 8-61), 
depicted in Figure 10. Seven patients expired prior to engraftment (6.9%) and were not 
evaluable for GVHD. 
 
Figure 9. Time to neutrophil engraftment:     Figure 10. Time to platelet engraftment: 
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Table 20. Patterns of cutaneous involvement in acute GVHD: 
Cutaneous Involvement No. of patients 
Maculo-papular rash 14 
Follicular GVHD 1 
Flexural involvement 1 
Dyspigmentation 1 
 
Oral mucosal involvement was always white reticulate plaques similar to lichen 
planus. Involvement of the glans penis was seen in 2 patients, 1 had erythema and 
erosions and the other had violaceous plaques similar to lichen planus, along with oral 
mucosal and lip involvement.  
Of the 15 unrelated donor transplants, acute muco-cutaneous GVHD was seen in 5 
patients (33.3%), of the sibling donor transplants, 18 patients (22.8%) and of the parent 
donors, 2 patients (25%).  
Of the BMTs, 6 patients (20%) had acute muco-cutaneous GVHD and of the 
PBSCTs, 19 patients (26.8%) had acute muco-cutaneous GVHD. The patient with CBT 
did not develop GVHD. 
Median time to onset of acute muco-cutaneous GVHD was 32 days (range, 11 to 
95), depicted in Figure 12. 
Figure 12. Time to onset of acute GVHD: 
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Acute gastrointestinal GVHD was seen in 35 patients (36.8%), and the 
histopathology was consistent with the diagnosis of GVHD. Acute liver GVHD was seen 
in 29 patients (30.5%). 
Totally, 52 patients (50.9%) had acute GVHD. 
Chronic GVHD: 
Chronic GVHD, as defined by the onset of clinical features of GVHD after 100 
days post transplant, was evaluated in 61 patients who followed up for >100 days.  
Fifteen patients (24.6%) had chronic muco-cutaneous GVHD. Cutaneous 
involvement was mostly seen as violaceous plaques over the lips, face and body, a single 
patient had reticulate hyperpigmented plaques over the palms and soles, 1 patient had 
vitiliginous GVHD and 2 patients had a maculopapular rash. Involvement of the glans 
was seen in only 1 patient, who had white reticulate plaques. Nail involvement was seen 
in 1 patient. Sclerodermoid GVHD was not seen.  
Clinical presentations of chronic muco-cutaneous GVHD are summarized below in 
Table21. 
Table 21. Patterns of muco-cutaneous involvement in chronic GVHD: 
Morphological type of 
presentation Number % 
Lichenoid: 
1. Skin 
2. Oral 
3. Genitals 
4. Nails 
 
8 
10 
1 
1 
 
53.3% 
66.7% 
6.7% 
6.7% 
Sclerodermatous: - - 
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Others: 
1. Maculopapular 
rash 
2. Vitiliginous 
GVHD 
 
2 
1 
 
13.3% 
6.7% 
 
Of the 15 unrelated donor transplants, chronic muco-cutaneous GVHD was seen 
in 2 patients (13.3%), of the sibling donor transplants, 11 patients (13.9%) and of the 
parent donors, 2 (25%).  
Of the BMTs, none developed chronic muco-cutaneous GVHD whereas of the 
PBSCTs, 15 patients (21.1%) did. The patient with CBT did not develop GVHD. 
Median time to onset of chronic muco-cutaneous GVHD was 231 days (range, 
130 to 497) shown in Figure 13.  
Figure 13,  Time to onset of chronic GVHD: 
 
Prior acute muco-cutaneous GVHD was seen in 3 patients (20%) with chronic 
muco-cutaneous GVHD. Prior acute gut GVHD was seen in 9 of these patients (60%) and 
prior liver GVHD in 6 (40%) of them.  
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Chronic gastrointestinal GVHD was seen in 2 patients (3.3%), both had prior 
acute gut GVHD, 1 had prior acute muco-cutaneous GVHD and the other had prior acute 
liver GVHD. Chronic liver GVHD was seen in 2 patients (3.3%), both had prior acute gut 
GVHD and 1 had prior acute muco-cutaneous GVHD.  
Totally, 17 patients had chronic GVHD, of whom 13 had a history of prior acute 
GVHD. 
Clinical pattern of chronic GVHD based on presence of prior acute GVHD is 
summarized in Table 22. 
Table 22. Clinical pattern of chronic GVHD: 
 Progressive Quiescent De novo Total 
Number 1 12 4 17 
% 5.8 70.6 23.5 100 
 
Chronic GVHD was further classified on the basis of extent of involvement. 
Extensive chronic GVHD was seen in 2 patients, and limited chronic GVHD was seen in 
all the other patients.  
The incidence of muco-cutaneous GVHD, both acute and chronic, was 37 out of 95 
patients (38.9%). Gastrointestinal GVHD was seen in 35 patients (36.8%), liver GVHD in 
31 patients (32.6%). Totally, 56 patients had GVHD (58.9%). 
Histopathology: 
Skin biopsies were performed in 37 patients, of which 7 patients had 2 or more 
biopsies. A total number of 48 biopsy specimens were taken to rule out GVHD. Skin 
biopsies were consistent with GVHD in 31 patients. Out of 38 biopsies which showed 
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acute GVHD, 7 had grade 1 changes, 20 had grade 2, 11 had grade 3 and none had grade 
4 changes. A single patient had features of chronic lichenoid GVHD. In 2 patients, during 
the same episode, 2 sites were biopsied and 1 site showed GVHD. In another 3 patients, 
both sites showed GVHD, of differing grades. In 3 patients, the biopsy was not consistent 
with GVHD. One patient had 4 biopsies at different times, 3 of which were done to rule 
out GVHD; 2 were consistent with GVHD, grades 1 and 3 in chronological order.  
Clinico-histopathological correlation was done for acute cutaneous GVHD. If at 
the same time, with the same clinical stage, 2 histopathological grades from 2 biopsy 
samples were present, the higher grade was used. Level of agreement between clinical 
cutaneous grade and histological grade was checked in 27 biopsies, it was found that 
there was a negative agreement between the grades (Kappa=-0.169, p= 0.325).  
Table 23 enlists the clinical and histological grades. 
Table 23. Clinical and histological grades of acute GVHD:  
Clinical grade Histological grade 1 2 3 4 
1 - 10 4 - 
2 1 2 1 - 
3 4 1 4 - 
4 - - - - 
 
Risk factors for GVHD:  
The following risk factors were analyzed for acute and chronic GVHD in Table 24 and 
25 respectively. 
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Table 24. Risk factors for acute GVHD: 
Variable Risk 95% Confidence intervals p-value 
Patient age <15 years 
Patient age ≥15 years 
1 
5.600 
 
2.306 - 13.600 
 
0.000 
Donor age <15 years 
Donor age ≥15 years 
1 
5.494 
 
2.156 - 14.003 
 
0.000 
Source of hematopoietic stem 
cells: Bone marrow 
Peripheral blood  
1 
 
3.947 
 
 
1.540-10.113 
 
 
0.004 
Gender matched or male 
donor to female recipient 
Female donor to male 
recipient 
1 
 
1.220 
 
 
0.523-2.847 
 
 
0.646 
ABO incompatibility 1.002 0.444-2.260 0.997 
Donor relation: sibling 
Parents 
Unrelated 
1 
2.000 
3.333 
 
0.345-11.578 
0.850-13.069 
 
0.439 
0.084 
Nonmyeloablative 
conditioning 
Myeloablative Conditioning 
1 
 
0.720 
 
 
0.319-1.625 
 
 
0.429 
Related, HLA matched 
Mismatched 
1 
2.000 
 
0.345- 11.576 
 
0.439 
Unrelated, HLA matched 
Mismatched 
1 
4.500 
 
0.190- 106.813 
 
0.352 
 
Increasing patient age and donor age were found to be statistically significant risk 
factors for acute GVHD; the risk was about 5 times higher if the age was more than 15 
years. If the source of stem cells was peripheral blood compared to bone marrow, after 
excluding the single patient with cord blood transplantation, the risk of acute GVHD was 
almost 4 times, and statistically significant. Gender and blood group mismatch were not 
found to be significant risk factors. If the relationship of the donor was a parent rather 
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than a sibling, or the donor was unrelated, the risk was higher, but not statistically 
significant. For related or unrelated transplants, if the HLA type was not identical, the risk 
was higher, but not significant. Myeloablative versus reduced intensity conditioning 
regimen was found to be not significant. Most of the patients received Cyclosporine and 
Methotrexate combination, therefore the analysis did not reach statistical significance. 
Table 25. Risk factors for chronic GVHD: 
Variable Risk 95% Confidence intervals p-value 
Patient age <15 years 
Patient age ≥15 years 
1 
2.191 
 
0.660- 7.270 
 
0.200 
Donor age <15 years 
Donor age ≥15 years 
1 
5.192 
 
1.056- 25.541 
 
0.043 
Source of hematopoietic stem cells: 
Bone marrow 
Peripheral blood 
1 
 
6.932 
 
 
0.830- 57.891 
 
 
0.074 
Gender matched or male donor to 
female recipient 
Female donor to male recipient 
1 
 
1.681 
 
 
0.466- 6.060 
 
 
0.427 
ABO incompatibility 0.974 0.317- 2.987 0.963 
Donor relation: sibling 
Parents 
Unrelated 
1 
2.846 
1.138 
 
0.363- 22.316 
0.196- 6.600 
 
0.319 
0.885 
Nonmyeloablative conditioning 
Myeloablative Conditioning 
1 
0.317 
 
0.095- 1.053 
 
0.061 
Related, HLA matched 
Mismatched 
1 
4.625 
 
0.689- 31.046 
 
0.115 
Unrelated, HLA matched 
Mismatched 
1 
0.250 
 
0.007- 8.560 
 
0.442 
Prior acute GVHD 2.470 0.694- 8.790 0.163 
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Increasing donor age was found to be a statistically significant risk factor for 
chronic GVHD; the risk was about 5 times higher if the donor was more than 15 years 
old. With increasing patient age or if the source of the stem cells was peripheral blood 
compared to bone marrow, there was increased risk of chronic GVHD, but it did not 
reach statistical significance. Gender or blood group mismatch were not found to be 
statistically significant risk factors. The risk of chronic GVHD if the donor was not a 
sibling, but a parent, was higher, but did not achieve statistical significance. Unrelated 
donor transplant was not a statistically significant risk factor for chronic GVHD. 
Myeloablative conditioning compared to reduced intensity conditioning was not found to 
be significant. Mismatched HLA type, if unrelated, and prior acute GVHD were 
associated with increased risk for chronic GVHD, but they were not statistically 
significant. For related transplants, mismatched HLA type was not found to be a risk 
factor. GVHD prophylactic regimens could not be analyzed as all the patients had 
received Cyclosporine and Methotrexate. 
Therapy: 
 GVHD was treated with corticosteroids as 1st line therapy, if they did not 
respond, or progressed after 7 days of appropriate steroid therapy, they were treated as per 
the primary physician’s discretion and the therapies used included Mycophenolate, 
Basiliximab and Rituximab. In a single patient, mesenchymal stem cells were tried. 
Response to therapy of acute GVHD, when clinically significant disease was treated, is 
summarized in Figure 14. 
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DISCUSSION 
This study was done to determine the incidence of muco-cutaneous GVHD in a 
tertiary referral centre in south India between March, 2009 and July, 2010.  
Demographic profile: 
Out of 102 patients, 43.1% were children. The median age was 20.5 years, 
signifying that older patients were not considered for transplantation as often as children 
were. Male: female ratio of the recipients was almost 2:1. Patients were mostly of the 
higher socio-economic background (88.2%) and were based in India. 
Patient profile: 
The primary diagnosis was most often AML and thalassemia, followed by aplastic 
anemia and ALL, then myelodysplastic syndrome, CML, biphenotypic leukemia, 
Fanconi’s anemia, Kostmann syndrome, pure red cell aplasia, juvenile myelomonocytic 
leukemia, paroxysmal nocturnal hemoglobinuria, Wiskott Aldrich syndrome and severe 
combined immunodeficiency in decreasing order of frequency.  
Patients were asked about a prior history of blood transfusions, which almost all 
of them had. 
Donor compatibility profile: 
The donors were most often siblings (77.5%), followed by unrelated donors 
(14.7%), and parents (7.8%). Donors of all the thalassemia patients were relatives. 
Unrelated donor transplants were mostly done in patients with AML.  Identical HLA 
typing was found in most of the related donors, 92%. ABO blood group incompatibility 
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was fairly common, 45.1%. Gender mismatch, from a female donor to a male recipient 
was seen in 33.3% of the transplants, of which parous donors were 38.2%. 
Transplantation profile: 
PBSCT was the most common type of transplant, and was performed in all the 
AML, ALL, CML, biphenotypic leukemia and aplastic anemia patients. BMTs continued 
to be done in most of the thalassemics. Cord blood transplant was performed in only one 
patient, who was diagnosed to have Wiskott Aldrich syndrome prenatally. He was one of 
twins, with an older sibling diagnosed to have the same disease.  
More than half the patients received myeloablative conditioning regimens, 53.9%, 
of which Thiotepa, Treosulphan and Fludarabine was the combination used most often, 
followed by TBI and Cyclophosphamide. The reduced intensity conditioning regimens 
used most often consisted of Busulphan, Cyclophosphamide and ATG or Fludarabine and 
Melphalan.  
The median time to engraftment of neutrophils was 16 days, (range, 9-57) and 
time to engraftment of platelets was 17 days (range, 8-61), slightly longer than two 
weeks, mentioned by Deeg et al.15 
Follow up period: 
 The median follow up was 5½ months. The first patient was followed up for 
almost 1½ years, and the last patient for three months. 
Graft versus host disease:  
As the primary outcome of the study, the incidence of GVHD was evaluated in 95 
patients, as seven patients expired prior to engraftment. The incidence of GVHD was 
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found to be 58.9%. The incidence of GVHD is similar to that mentioned in Western 
literature, upto 80% stated by Wenzel et al.4  
The incidence of muco-cutaneous GVHD was found to be 38.9%. Although the 
skin, gut and liver were found to be involved in decreasing order of frequency, as 
mentioned by Goddard et al,40 of all the patients with GVHD, muco-cutaneous GVHD 
comprised only 66.1%, which is lower than Western literature,14 probably due to 
difficulty in identifying the faint rashes of acute GVHD, especially after most of the 
conditioning regimens cause a generalized hyperpigmentation. 
Hyperacute GVHD: 
Hyperacute GVHD was seen in only one patient, incidence being lower than that 
mentioned by Saliba et al.51 It was seen on day 11, slightly later than the usual 
presentation within the first week.5 She had an unrelated donor and received peripheral 
blood stem cells. She had only cutaneous involvement with a maculopapular rash on the 
body; there was no hepatitis or features of vascular leakage as mentioned by Goker et al.5 
Response to therapy wasn’t prompt as opposed to an engraftment syndrome.15 
Acute GVHD: 
Incidence of acute GVHD was 50.9%, within the range 6-90% given by Aractingi 
et al and Fimiani et al. 38,42 
Acute muco-cutaneous GVHD was seen in 26.3% patients. Most patients had mild 
clinical stage 1 acute cutaneous GVHD (45.8%). Stage 4 was seen in only one patient, 
who had a matched unrelated donor transplant and received peripheral blood stem cells. 
She had a maculopapular rash on day 18 and progressed to have necrolysis in two days; 
this interval was really short compared to 19 days stated by Goiriz et al.18 She didn’t have 
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any mucosal involvement, again dissimilar to most of the patients described by Goiriz et 
al.18 She was refractory to steroid therapy and subsequently treated with Basiliximab.  
Clinical presentation of acute GVHD was most commonly a maculopapular rash, 
in 14 patients, of which only one progressed to have the appearance of necrolysis of the 
skin in the form of erosions, as described above. Flexural edematous plaques were seen in 
a single patient, similar to what is described as eczematoid chronic GVHD,77 which was 
grade 3 on biopsy. Follicular GVHD was seen clinically in one patient, who had biopsy 
features of grade 2 acute GVHD, similar to that described by Tani et al.57 However, a 
patient with a maculopapular rash had biopsy features suggestive of follicular GVHD, 
suggesting that the follicular epithelium was targeted early, as suggested by Friedman et 
al.56 Dyspigmentation over the arms, “leopard- like pigmentation” usually seen with 
chronic GVHD,9 was seen in one patient on day 60; however, the biopsy was consistent 
with grade 2 acute GVHD. Mucosal involvement was seen more commonly in the oral 
mucosa than the glans penis. Twelve patients had white reticulate plaques on the oral 
mucosa, and not erosions as described by Goiriz et al.18 One patient had erythema and 
erosions of the glans, being the sole manifestation of muco-cutaneous GVHD; and 
another had violaceous plaques on the glans. Oral mucosal involvement with only lips 
being involved as a cutaneous manifestation, seen as violaceous plaques, was seen in 6 
patients. In the patients with acute GVHD, 13 patients had only skin without mucosal 
involvement, one had only mucosal involvement of the glans penis and 12 had mucosal 
and skin involvement simultaneously. One patient had a maculopapular rash on day 18, 
clinical stage 2 and biopsy grade 3, which resolved; and thereafter he had violaceous 
plaques on the lips and reticulate white plaques on oral mucosa on day 78, clinical stage 2 
and biopsy grade 3.  
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Median time to onset of acute cutaneous GVHD was 32 days, comparable with 30-35 
days, mentioned by Hausermann et al and Deeg et al,3,15 but longer than 19 days 
mentioned by Schubert et al.52 
Chronic GVHD: 
Chronic GVHD occurred in 27.9% patients, consistent with older literature, at the times 
when most patients succumbed to acute GVHD.41,45 But the latest literature says that 
chronic GVHD is on the rise, upto 80%,7,8,46 especially in unrelated donor transplants.34,49 
If the patients were followed up longer, the percentage would probably have been higher. 
Median follow up of patients was 3.2 years (11 months to 5.4 years) in the study done by 
Fujii et al.47 
Chronic muco-cutaneous GVHD was seen in 24.6%. It was seen as violaceous 
plaques on the lips in three of the patients, who also had white reticulate plaques on oral 
mucosa. Violaceous plaques on the face or rest of the body were seen in three patients. 
Oral mucosal involvement was in the form of white reticulate plaques, seen in 10 patients 
(66.7%), slightly lower than 80% incidence mentioned in established data.42 Only oral 
mucosal involvement was seen in three patients, without cutaneous manifestations. Two 
patients had white reticulate plaques on the glans penis. Nail involvement was seen in a 
single patient with chronic GVHD as splitting, ridging and discoloration, biopsy of the 
nail was not done to confirm the diagnosis; the patient had concomitant mucosal GVHD, 
proven histopathologically. Incidence of nail involvement was much lower than 50% 
mentioned during the Turkish study.79 Reticulate hyperpigmented plaques with central 
atrophy and depigmentation on the palms and soles were seen in one patient. Lichen 
planus-like GVHD was seen in 80% of our patients with chronic GVHD, much higher 
than 9% mentioned by Schaffer,9 probably because of the short period of follow up in our 
66 
 
study. Vitiliginous GVHD with depigmented macules on the lips and palms was seen in a 
patient as late as 497 days post transplant, Fimiani et al described vitiligo like lesions38 
and Williams et al described leukoderma as GVHD.71 Maculopapular rash on the body 
without mucosal involvement was seen in two patients, similar to that described by 
Hymes et al;65 both of these had prior acute GVHD and developed the rash as 
immunosuppressive therapy for treatment of the acute GVHD was tapered.  
Median time to onset of chronic GVHD was 231 days (range, 130 to 497), longer 
than 4 months mentioned by Nghiem et al,69 but within the range 3 to 24 months given by 
Lee et al.8 
Quiescent chronic GVHD was seen in 70.6%, comprising the most common type 
in our setting. It was double that described by Aractingi et al.42 Progressive chronic 
GVHD was only found in 5.8%, much less than what was described, whereas the de novo 
type was 23.5%, similar to established data published by Aractingi et al.42 
Histopathology: 
The 31 patients whose histopathology was consistent with GVHD were treated as 
GVHD prior to the reporting of the biopsy. In three patients, whose biopsy was not 
consistent with GVHD, they were not treated as GVHD because of early presentation of 
the rash, prior to engraftment or the rash was not clinically typical of GVHD. Five 
patients had two sites biopsied simultaneously to rule out GVHD, three patients had 
GVHD in both the specimens, but two had GVHD in only one specimen, therefore, we 
suggest that performing a biopsy from two sites increases the yield of diagnosis. In a 
single patient, serial biopsies had been done at 15 and 34 days, when he had clinical 
stages 3 and 2 respectively, but a biopsy revealed grade 1 and 3, indicating that 
histopathological features take time to be established, as explained by Kuykendall et al.89 
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However, as described by Firoz et al,58 as the prevalence of GVHD is now described to be 
>30%, a skin biopsy need not be done to confirm acute GVHD, especially in the first 
month after the transplant.  
Clinico-pathological correlation in patients with acute cutaneous GVHD revealed 
a negative correlation between clinical stage and histopathological grade, consistent with 
previously established data.30  
Risk factors for GVHD: 
We also tried to find the relevance of previously known risk factors for acute and 
chronic GVHD in our population. However, as the patients had differing diagnoses and 
the sample size was small; many factors did not reach statistical significance. 
Acute GVHD: 
Increasing patient age and donor age were found to be statistically significant risk 
factors for acute GVHD; the risk was about 5 times higher if the age was more than 15 
years. PBSCT compared to BMT, the risk of acute GVHD was almost 4 times, and 
statistically significant. PBSCT is said to increase the risk of chronic not acute GVHD.5 If 
the relationship of the donor was a parent rather than a sibling, or the donor was 
unrelated, the risk was higher, but not statistically significant. For related or unrelated 
transplants, if the HLA type was not identical, the risk was higher, but not significant. 
HLA mismatch is considered the main risk factor.15 Gender and blood group mismatch or 
myeloablative conditioning were found to be insignificant, unlike in other studies.35,36 
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Chronic GVHD: 
Increasing donor age was found to be a statistically significant risk factor for 
chronic GVHD; the risk being 5 times higher if the donor was over 15 years old. With 
increasing patient age or PBSCT, there was increased risk of chronic GVHD, but it did 
not reach statistical significance. The risk of chronic GVHD if the donor was not a 
sibling, but a parent, was higher, but did not achieve statistical significance. Unrelated 
donor transplant was not a statistically significant risk factor for chronic GVHD. Gender 
or blood group mismatch and myeloablative conditioning were not found to be 
statistically significant risk factors. Prior acute GVHD was associated with increased risk 
for chronic GVHD, but was not statistically significant. The main risk factor is thought to 
be prior acute GVHD,8,38 however, in the study in Japan, they found no difference in the 
incidence of chronic GVHD whether the patient had prior acute GVHD or not.47 
Mismatched HLA type was not found to be a statistically significant risk factor, whether 
related or not.  
Therapy: 
Around half the patients were responsive to steroid therapy; the others were 
treated with Mycophenolate, Basiliximab or Rituximab. Mesenchymal stem cells were 
used in a single patient, but he succumbed to the disease. 
Course of the patients: 
 Many patients, 27.5% expired, mostly due to infectious causes. Two patients died 
of GVHD. Three patients had primary graft failure and another three relapsed.  
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CONCLUSION 
• The incidence of acute muco-cutaneous GVHD was 26.3%, the most common 
presentation being a maculopapular rash. Median time to onset was 32 days 
(range, 11 to 95). 
• The incidence of chronic muco-cutaneous GVHD was only 24.6%, probably due 
to short follow up period. Median time to onset was 231 days (130-497). 
• Incidence of lichenoid chronic GVHD was 80%. 
• Maculopapular rash occurred in 2 patients as part of chronic GVHD, both were 
refractory to steroid therapy. 
• Quiescent chronic GVHD is the commonest type of chronic muco-cutaneous 
GVHD in India. 
• Clinical and histopathological grades of acute cutaneous GVHD didn’t show 
correlation in our study. 
• Among the risk factors, older patient age, donor age and PBSCT were found to be 
significant for acute GVHD and older donor age for chronic GVHD. 
• Mortality rate was 27.5%. 
• The incidence of GVHD was found to be 58.9% in India, muco-cutaneous GVHD 
was 38.9%, gut GVHD was 36.8% and liver GVHD was 32.6%. 
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LIMITATIONS 
1. Rashes of acute graft versus host disease are often very faint and difficult to 
recognize on darker skin, especially as the conditioning regimen causes most of 
the patients to become hyperpigmented. 
2. Judgment of the presence of acral erythema is difficult. 
3. Once the diagnosis of graft versus host disease was established, skin biopsy was 
not repeated, when the patient progressed to a worse clinical grade in a few days. 
4. Acute and chronic GVHD was classified by the traditional 100 day criteria as the 
definitions for overlap in muco-cutaneous GVHD are not well defined. 
5. Evaluation of sclerodermatous GVHD was not possible due to the short duration 
of the study. 
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RECOMMENDATIONS 
• All hematopoietic stem cell transplant patients should be regularly followed up by 
a dermatologist. 
• Any rash occurring prior to engraftment should be considered for biopsy to rule 
out hyperacute GVHD. 
• A new staging system is required for acute GVHD which includes purely mucosal 
involvement. 
• Overlap syndrome should be more clearly defined in patients with muco-
cutaneous GVHD. 
• Patients need to be followed up for many years to be able to assess sclerodermoid 
spectrum of GVHD. 
• Routinely performing a skin biopsy in the first month in case a rash develops is 
not indicated in our population as the incidence of graft versus host disease is 
38.9% and many patients develop GVHD in other organs as well. However, 
histopathological diagnosis is important to rule out another diagnosis where 
considered, especially infections. 
• Biopsy from two sites may be more helpful since the yield is better. 
• Histopathological grading of acute cutaneous GVHD does not correlate with 
clinical staging and so may not be helpful. 
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SUMMARY 
Background: 
Allogeneic hematopoietic stem cell transplants are being increasingly performed 
for various indications. GVHD is the most common complication of hematopoietic stem 
cell transplantation. Skin is the organ affected most often by this process. 
Objective:  
 To determine the incidence of muco-cutaneous GVHD, describe the clinical 
presentations, establish the clinico-pathological correlation of acute cutaneous GVHD and 
analyze the risk factors for GVHD in India.  
Methodology: 
 A single centre prospective longitudinal study was performed in Christian Medical 
College, Vellore with 102 patients from March, 2009 to July, 2010. All patients 
undergoing hematopoietic stem cell transplantation were screened and recruited into the 
study prior to the transplant, after obtaining a written informed consent and an assent 
form for children where applicable, which was approved by the institutional review 
board. All patients were examined by the principal investigator prior to the transplant and 
periodically thereafter, every week or month, as the patient followed up, or if any muco-
cutaneous symptom appeared. The presence and extent of skin rash and oral mucosal 
involvement was clinically assessed, photographs were taken and biopsies performed 
where indicated, to help confirm the diagnosis, with the patient’s consent. Routine 
investigations, including total count, differential count and liver function tests were done 
regularly. Demographic data was collected from the records, as was the pre-transplant 
diagnosis, donor related information, stem cell source and conditioning regimen. The 
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calculated sample size was 92. All statistical analysis was performed using SPSS 11.0 for 
windows (SPSS Inc, Chicago, IL).  Frequency and percentages were used to describe the 
distribution of categorical variables, median and ranges were used to describe continuous 
variable that were not normal distributed. Chi-square test was used to assess the 
association between categorical variables. Continuous variables were compared using t-
test.  Weighted kappa statistic was used to assess agreement between clinical and 
histopathological grades of GVHD; squared weights were employed. The agreement was 
analyzed using R 2.8.0 (“irr” library). Logistic regression was employed to estimate the 
adjusted odds ratios as measure of risk for GVHD against potential risk factors. A p-value 
of less than 0.05 was considered statistically significant.  
Results: 
Out of a sample size of 102 patients, 95 were evaluated for acute GVHD and 61 
for chronic GVHD. Median age was 20.5 years. Males comprised 65.7% of the patient 
population. The most common primary diagnosis was AML, followed by thalassemia. 
Donors were mostly siblings, 77.4%; and unrelated donors comprised 14.7%. HLA type 
was identical in 92% of related transplants. ABO blood group incompatibility was seen in 
45.1%. Gender mismatch from a female donor to male recipient was 33.3%. Peripheral 
blood was the most common source of hematopoietic stem cells, in 69.6%. Myeloablative 
conditioning was given for 53.9% patients. Cyclosporine and Methotrexate combination 
was given as prophylaxis for 94.1% patients. The median time to engraftment of 
neutrophils was 16 days (range, 9 to 57) and platelets was 17 days (range, 8 to 61). Acute 
muco-cutaneous GVHD was seen in 26.3% and chronic in 24.6% patients. Median time 
to onset of acute GVHD was 32 days (range, 11 to 95) and chronic GVHD was 231 
(range, 130 to 497). Incidence of GVHD was found to be 58.9% in our population. There 
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was a negative clinico-pathological correlation in acute cutaneous GVHD. Most of the 
risk factors analyzed did not reach statistical significance due to the presence of a 
heterogeneous population with differing diagnoses. However, older patient and donor 
age, and PBSCT were found to be significant risk factors for acute GVHD and older 
donor age for chronic GVHD. 
Conclusion:  
The incidence of acute muco-cutaneous GVHD was 26.3%, most commonly a 
maculopapular rash occuring around 32 days (range, 11 to 95). The incidence of chronic 
muco-cutaneous GVHD was 24.6%, most commonly lichenoid GVHD occurring around 
day 231 (130-497). Quiescent chronic GVHD is the most common type. 
Clinical and biopsy grades had no correlation in acute cutaneous GVHD. Older 
patient and donor age and PBSCT were risk factors for acute GVHD and older donor age 
was a significant risk factor for chronic GVHD. 
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ANNEXURES 
Annexure 1 
Subject Information Sheet / Informed consent Form to Participate in a Research 
Study 
 
Study title: “Study of the incidence of muco-cutaneous Graft versus Host Disease among 
patients undergoing allogenic hematopoeitic stem cell transplantation” 
 
Principal investigator: Dr. Anisha Chandy, Department of Dermatology, CMC, Vellore 
 
Institution: Christian Medical College, Vellore (Departments of Dermatology and 
Haematology) 
 
Introduction: This study is being done to find out the number of patients that have a 
reaction to the bone marrow transplant in the skin or mucosa. It requires that you should 
be regularly followed up to watch for any muco-cutaneous signs. 
 
Study procedures: You will be examined by doctors in the Haematology department and 
will be asked to undergo tests which are done as part of routine protocol for any patient 
undergoing hematopoeitic stem cell transplantation. In case a clinical diagnosis is 
difficult, a biopsy from the skin or mucosa may need to be done. A photograph, if 
necessary, will be taken with your permission. No additional tests will be done. 
 
Benefits/risks: None. 
 
Confidentiality/Privacy:  Strict privacy will be maintained during the interview, clinical 
examination and information of laboratory results. Your name will not appear on the 
study records, but will be linked to them by a study number which will be kept 
confidential by the study investigator. 
 
Contacts: If you experience any unforeseen difficulty from the study, you may come back 
to the Haematology department or the Emergency department immediately or contact Dr. 
Anisha Chandy at 2283403. 
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If you have any queries regarding the Ethical aspects of the study you can contact the 
below address: 
Ethics Committee address/ Chairperson contact number:  
Dr. L. Jeyaseelan Ph.D. 
Secretary, Institutional Review Board, 
(Ethics Committee) 
Christian Medical College,  
Vellore- 632 002, Tamil Nadu, India 
91 416 2284205 / 2262703 
 
Consent by the Subject: 
Signature of the subject: 
 
Date: 
Name: 
Hospital No.: 
Serial No:  
 
Signature of impartial witness (if applicable)/ signature of the LAR (if illiterate): 
Relationship to the patient: 
Signature: 
 
Name: 
Date: 
 
Person conducting ICF/ designate (PI/Co-PI): 
Signature: 
 
Date: 
Name: 
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Annexure 2 
Departments of Dermatology & Haematology, 
Christian Medical College, 
Vellore- 632004 
Assent Form for Children 
 
Title of Study: 
Study of the incidence of muco-cutaneous Graft versus Host Disease among patients 
undergoing allogeneic hematopoietic stem cell transplantation” 
 
Principal Investigators: 
Dr. Anisha Chandy, Department of Dermatology, CMC, Vellore 
 
Why are we doing this study? 
This study is being done to find out the number of patients that have a reaction to the 
bone marrow transplant in the skin or mucosa. It requires that you should be regularly 
followed up to watch for any muco-cutaneous signs. 
 
What will happen during the study? 
You will be examined by doctors in the Haematology department and will be asked to 
undergo tests which are done as part of routine protocol for any patient undergoing 
hematopoietic stem cell transplantation. In case a clinical diagnosis is difficult, a biopsy 
from the skin or mucosa may need to be done. A photograph, if necessary, will be taken 
with your permission. No additional tests will be done. 
 
Are there good things and bad things about the study? 
No. 
 
Who will know about what I did in the study? 
If you are a part of this study, your name and address will not be given to anyone without 
your consent. 
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Can I decide if I want to be in the study?  
Nobody will be angry or upset with you if you do not want to be in this study. We are 
talking to your parents/ legal guardians about the study and you should talk to them about 
it too.                                
 
Assent: 
 
I was present when________________ read this form and gave my verbal assent. 
 
 
 
Name of the Patient                                         Signature                                       Date 
 
 
Name of the person who obtained consent      Signature                                       Date 
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Annexure 3 
PROFORMA 
Serial No. 
Name      Hospital No.         Age 
Address      
Sex 
Occupation 
Marital status 
Religion 
Education( highest class studied) 
Locality-urban 
     -rural 
Monthly income: 
 
Diagnosis: 
Duration of illness: 
Type of transplant: 
Date of transplant: 
Source of haematopoietic stem cells: 
HLA type: 
Blood group: 
History of prior drug allergies: 
History of prior blood transfusions 
 
Name of donor: 
Age: 
Sex: 
Hospital No: 
Relation: 
HLA type: 
Blood group: 
History of pregnancy: 
88 
 
History of prior blood transfusions 
 
Pre-transplant checkup: 
Date of examination: 
Conditioning regimen: 
GVHD prophylaxis: 
Clinical findings: 
Post-transplant checkup: 
Acute GVHD: 
Grade: 
Overlap syndrome: 
Chronic GVHD: 
Lichenoid: 
Sclerodermoid: 
Limited: 
Extensive: 
 
 
Lab parameters 
 
 
Date  Total 
Count 
Differential 
Count 
Bilirubin Biopsy 
No. 
Histopathological 
grade/ findings 
      
      
      
      
      
      
      
 
Clinico-pathological co-relation: 
 
Date Extent 
of 
Rash 
Distribut
ion 
Morph
ology 
Mucosal 
involvement 
Hair 
involvem
ent 
Nail 
involvem
ent 
Icteru
s 
Di
arr
ho
ea 
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Annexure 4 
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GLOSSARY TO THE MASTER TABLE 
Sex: 
1. Male 
2. Female 
 
Mstatus: Marital status 
 0.   Not applicable 
1. Married 
2. Single 
3. Widow 
 
Locat: Locality 
1. Urban 
2. Rural 
 
Diag: Diagnosis: 
1. Thalassemia 
2. Acute myeloid leukemia (AML) 
3. Acute lymphoblastic leukemia (ALL) 
4. Aplastic anaemia 
5. Myelodysplastic syndrome 
6. Biphenotypic leukemia 
7. Kostmann syndrome 
8. Fanconi’s anaemia 
9. Pure red cell aplasia 
10. Juvenile myelomonocytic leukemia 
11. Paroxysmal nocturnal hemoglobinuria 
12. Chronic myeloid leukemia (CML) 
13. Wiskott Aldrich Syndrome 
14. Severe combined immunodeficiency 
 
Sour: Source of haematopoeitic stem cells: 
1. Bone marrow 
2. Peripheral blood 
3. Cord blood 
 
HLA type: 
1. Identical 
2. 9/10 
3. Haplomatch 
4. 5/6 
5. 7/8 
6. 8/10 
7. 4/6 
 
Bld grp: Blood group: 
1. O+ 
2. B+ 
3. AB+ 
4. A+ 
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5. A- 
6. O- 
7. B- 
8. AB- 
 
Drug aller: History of prior drug allergies: 
 0. No 
 1. Yes 
 
Bld trans: History of prior blood transfusions: 
0. No 
1. Yes 
 
Relat: Donor relation: 
 0.   Unrelated 
1. Sister 
2. Brother 
3. Father 
4. Mother 
 
Preg: History of pregnancy: 
0. No 
1. Yes 
 
Cond: Conditioning regimen: 
1.   Fludarabine and Melphalan 
2. Busulphan, Cyclophosphamide and Anti-thymocyte globulin (ATG) 
3. Total body irradiation (TBI), Cyclophosphamide and ATG 
4. Etoposide, TBI, Cyclophosphamide and ATG 
5. Idarubicin, Cytarabine, Fludarabine and Melphalan (FLAG-IDA) 
6. Fludarabine and Cyclophosphamide 
7. TBI and Cyclophosphamide 
8. Busulphan and Cyclophosphamide 
9. Idarubicin, Cytarabine and Fludarabine  
10. Fludarabine, Cyclophosphamide and ATG 
11. Fludarabine and TBI 
12. Busulphan, Fludarabine and Melphalan 
13. Thiotepa, Treosulphan and Fludarabine 
14. Busulphan, Cyclophosphamide and Melphalan 
15. Busulphan, Etoposide and Cyclophosphamide 
16. Fludarabine and Busulphan 
17. Cyclophosphamide and ATG 
18. Treosulphan and Fludarabine 
 
Px: GVHD prophylaxis: 
1. Cyclosporine (CsA) and Methotrexate 
2. Cyclosporine 
3. Methotrexate 
4. Methotrexate and Tacrolimus 
5. CsA & Mycophenolate moefetil (MMF) 
94 
 
 
Rx: Treatment: 
0. No 
1. Methyl Prednisolone 
2. Mycophenolate 
3. Methyl prednisolone and Mycophenolate 
4. Methyl prednisolone, Mycophenolate, Basiliximab 
5. Methylprednisolone and basiliximab 
 
E_ANC: Neutrophil engraftment 
E-plts: Platelet engraftment 
 
Ac GVHD: Acute GVHD 
Chr GVHD: Chronic GVHD 
Liver: Liver GVHD 
Gut: Gastrointestinal GVHD 
0. No 
1. Yes 
 
FU1: First follow up 
 
GVHD: 
0. No 
1. Mucosal 
2. Cutaneous 
3. Skin and mucosa 
 
Gd: Clinical grade: 
0. <25% body surface area involvement 
1. 25-50% body surface area involvement 
2. >50% involvement 
3. Bullae 
 
Bx Gd: Histopathological grade: 
 1.  Basal vacuolar change 
 2.  With dyskeratotic keratinocytes as well 
3.  With focal clefting of the basal layer  
4.  Total separation of the epidermis from dermis  
 
FU2: Second follow up 
FU3: Third follow up 
FU4: Last follow up 
 
Relap: Relapse 
 
Exp: Expired 
 
 
GVHD figures, 
















Sno Hos.No Age Sex Mstatus Edu Locat Diag Source HLA Bld grp Drug aller Bld trans D_Age D_Sex Relat
1 359345D 15 1 0 3 1 2 2 1 1 0 1 26 2 1
2 029021D 9 2 0 1 1 1 1 1 3 0 1 4 2 1
3 359149D 42 2 1 3 2 2 2 4 4 1 1 45 1 2
4 339446D 23 1 2 5 1 2 2 2 1 0 1 45 1 0
5 330935D 21 1 2 6 2 3 2 6 3 0 1 45 1 0
6 387868D 54 1 1 3 1 2 2 1 4 1 1 56 1 2
7 137279D 42 2 1 3 1 4 2 1 4 0 1 38 1 2
8 386854D 58 1 1 4 1 4 2 1 1 0 1 44 1 2
9 301205D 35 1 1 5 1 4 2 1 2 0 1 38 2 1
10 363027D 53 2 1 3 1 5 2 1 2 1 1 58 1 2
11 385496D 32 1 1 6 1 6 2 1 1 0 1 24 1 2
12 275604D 1 1 0 0 1 7 1 1 1 0 1 11 2 1
13 373321D 32 2 1 3 2 4 2 1 1 0 1 35 1 2
14 159107D 7 1 0 1 1 1 1 1 2 0 1 7 2 1
15 424943D 28 1 1 3 1 2 2 1 1 0 1 30 2 1
16 281179D 48 2 1 3 1 4 2 1 1 0 1 40 1 2
17 347234D 26 1 2 6 1 2 2 1 4 0 1 24 2 1
18 408536D 40 1 1 2 1 2 2 1 1 0 1 39 1 2
19 393560D 36 1 1 6 1 2 2 1 1 1 1 39 1 2
20 318634D 11 2 0 2 1 1 1 1 1 0 1 9 2 1
21 380311D 43 1 1 4 1 2 2 5 2 0 1 50 1 0
22 394217D 30 1 1 5 1 2 2 2 2 0 1 22 1 0
23 448962C 49 1 1 4 1 2 2 1 4 1 1 41 1 2
24 792367C 12 1 0 1 1 1 1 1 2 0 1 24 1 2
25 437129D 10 1 0 1 1 2 2 1 4 0 1 17 2 1
26 528515B 48 1 1 5 1 2 2 1 4 0 1 46 1 0
27 665228C 4 1 0 0 2 1 1 1 1 0 1 13 2 1
28 386986D 12 2 0 2 1 4 2 4 1 0 1 22 1 2
29 418816D 38 1 1 6 1 3 2 4 4 0 1 34 2 1
30 430307D 25 2 2 5 1 4 2 2 4 1 1 22 1 2
31 363848D 10 1 0 2 1 8 1 1 2 0 1 3 2 1
32 415095D 22 1 2 5 1 2 2 1 1 1 1 25 1 2
33 441405D 58 2 1 6 1 2 2 1 1 0 1 49 1 2
34 197353D 14 1 0 3 1 1 1 1 2 0 1 10 1 2
35 217525D 9 2 0 1 1 1 1 1 7 0 1 6 2 1
36 486153D 2 2 0 0 1 1 1 1 1 0 1 9 2 1
37 607951C 4 2 0 0 1 9 1 1 1 0 1 11 1 2
38 401517D 11 1 0 2 1 4 2 1 2 0 1 7 1 2
39 467638D 47 1 1 3 2 2 2 1 4 0 1 45 1 2
Sno Hos.No Age Sex Mstatus Edu Locat Diag Source HLA Bld grp Drug aller Bld trans D_Age D_Sex Relat
40 938956C 8 2 0 1 1 1 1 1 1 0 1 3 1 2
41 481690D 34 2 1 6 1 2 2 1 1 0 1 34 1 2
42 443770D 22 2 2 5 1 5 2 1 6 0 1 26 2 1
43 572223C 7 2 0 1 1 1 1 1 2 0 1 42 1 3
44 398586D 9 1 0 1 1 2 2 3 4 0 1 35 2 4
45 638644C 5 1 0 0 1 1 1 1 4 0 1 8 2 1
46 385444D 17 2 0 3 1 1 2 1 4 0 1 55 1 3
47 516034D 3 1 0 0 1 10 2 1 1 0 1 4 2 1
48 381248D 47 1 1 5 1 5 2 2 1 0 1 28 1 0
49 384952D 35 1 1 6 1 2 2 2 3 0 1 33 1 0
50 544858D 28 1 1 6 1 3 2 1 1 0 1 24 1 2
51 371294D 8 2 0 1 1 1 1 4 1 0 1 26 2 4
52 453019D 31 1 1 6 1 6 2 1 2 0 1 33 1 0
53 543672D 3 2 0 0 1 4 2 1 3 1 1 39 1 3
54 325613D 25 1 2 6 1 5 1 2 4 0 1 33 1 0
55 329067D 11 1 0 2 1 1 1 1 6 0 1 4 2 1
56 377904D 54 1 1 3 2 4 2 1 4 0 1 60 1 2
57 465317D 34 1 2 5 1 2 2 1 1 1 1 36 2 1
58 200245D 39 1 1 4 2 3 2 1 3 0 1 34 2 1
59 551137D 14 1 0 3 1 1 1 1 4 0 1 11 2 1
60 611136C 18 1 0 4 2 2 2 2 1 1 1 43 2 0
61 451896D 34 1 1 5 1 2 2 1 1 0 1 42 1 2
62 452232D 23 1 2 5 1 11 2 1 1 0 1 32 1 0
63 046016D 10 1 0 1 1 1 1 1 2 0 1 5 1 2
64 045009D 3 1 0 0 1 1 2 1 2 0 1 7 2 1
65 354423D 4 1 0 0 1 4 2 4 1 0 1 34 1 3
66 297850D 4 2 0 0 1 4 2 1 1 0 1 14 2 1
67 396304D 33 2 1 6 1 2 2 2 2 1 1 33 1 0
68 508501D 32 2 1 2 2 2 2 1 6 0 1 39 1 2
69 764652C 33 1 1 5 1 3 2 1 3 0 1 26 2 1
70 526096D 11 1 0 2 1 2 2 1 1 0 1 42 2 4
71 115870C 12 2 0 2 1 1 1 1 4 0 1 10 1 2
72 575869C 14 2 0 3 1 1 1 1 1 0 1 21 2 1
73 483616D 51 2 1 5 1 12 2 1 1 1 1 56 1 2
74 249086D 9 1 0 1 2 1 1 1 4 0 1 4 2 1
75 452069D 7 1 0 1 1 1 1 1 1 0 1 3 1 2
76 465938D 0.6 1 0 0 1 13 3 1 2 0 0 7 2 1
77 607088D 18 1 0 4 1 4 2 1 4 0 1 26 2 1
78 207392C 8 1 0 1 1 1 1 1 1 0 1 6 2 1
Sno Hos.No Age Sex Mstatus Edu Locat Diag Source HLA Bld grp Drug aller Bld trans D_Age D_Sex Relat
79 291985D 6 2 0 1 1 1 1 1 1 0 1 2 1 2
80 616661D 2 2 0 0 1 3 2 1 4 0 1 7 1 2
81 575339D 44 1 1 3 1 4 2 1 2 0 1 47 2 1
82 463024D 45 1 1 6 1 12 2 1 1 0 1 44 1 2
83 602097D 29 1 1 6 1 3 2 1 1 0 1 25 1 2
84 505773D 50 2 1 5 1 3 2 2 1 0 1 48 1 0
85 606551D 28 1 1 5 1 4 2 1 2 0 1 26 2 1
86 619327D 44 2 1 5 1 2 2 1 2 0 1 48 2 1
87 334171C 13 1 0 2 1 8 2 1 1 0 1 9 2 1
88 475365D 1 1 0 0 1 14 1 7 1 0 1 33 1 3
89 487826D 25 2 1 5 1 3 2 1 1 0 1 39 1 2
90 271409D 6 1 0 0 1 1 1 1 4 0 1 13 1 2
91 409351D 8 2 0 1 1 5 2 1 1 0 1 4 2 1
92 607417D 28 1 2 6 1 2 2 1 2 1 1 34 2 1
93 619264C 21 2 2 5 1 4 2 1 1 0 1 23 1 2
94 530345D 46 1 1 3 2 2 2 1 2 0 1 49 2 1
95 612836D 20 1 0 4 1 3 2 4 2 0 1 14 1 2
96 633221D 37 1 1 5 1 4 2 1 6 0 1 48 2 1
97 431214D 2 1 0 0 1 1 1 1 3 0 1 6 1 2
98 465204C 8 2 0 1 1 1 1 1 1 0 1 2 2 1
99 413636D 20 1 0 5 1 5 2 5 2 1 0 38 2 0
100 660012D 13 1 0 2 1 4 2 1 2 1 1 15 2 1
101 182812D 6 1 0 0 2 1 1 1 1 0 1 8 2 1
102 541802D 17 2 0 3 1 3 2 5 2 1 0 42 1 0
      
Sno Bld grp Preg Cond Px Rx E_ANC E-Plts Ac GVHD Chr GVHD Liver Gut FU1 GVHD Gd Bx Gd FU2 GVHD
1 2 0 1 1 1 15 14 0 1 1 0 35 0
2 4 0 2 1 0 15 36 0 0 0 0 15 0
3 4 0 1 1 1 11 11 1 1 0 1 27 0
4 1 0 3 1 3 18 0 1 0 1 1 11 0
5 2 0 4 1 3 12 13 1 1 1 1 14 0 61 1
6 4 0 5 1 0 19 11 0 0 0 0 5 0
7 5 0 6 1 1 15 14 1 0 1 1 7 0
8 2 0 1 1 3 14 14 1 1 1 1 4 0 172 3
9 2 1 6 1 2 17 28 1 0 0 1 10 0
10 2 0 1 1 0 13 0 0 0 0 0 7 0
11 1 0 7 1 3 13 10 1 1 1 1 11 0
12 4 0 8 1 0 17 49 0 0 0 0 7 0
13 4 0 6 1 2 14 14 1 0 0 1 3 0
14 2 0 2 1 0 19 30 0 0 0 0 12 0   
15 4 0 1 1 1 13 14 1 0 1 1 3 0
16 4 0 6 1 1 17 25 1 0 0 1 6 0
17 2 1 1 1 2 11 10 1 1 1 0 7 0
18 6 0 1 1 1 12 12 1 1 0 1 13 0
19 1 0 1 1 0 13 13 0 1 0 0 7 0
20 1 0 2 1 0 18 41 0 0 0 0 5 0
21 4 0 3 1 0 0 0 0 0 0 0 4 0
22 7 - 3 1 0 18 18 0 0 0 0 26 0
23 4 0 9 1 0 0 0 0 0 0 0 3 0
24 2 0 2 1 1 17 43 1 0 0 1 12 0
25 3 0 8 1 0 11 12 1 0 1 0 21 2 2 2
26 1 0 7 2 0 0 0 0 0 0 0 3 0
27 2 0 2 1 0 21 45 0 0 0 0 21 0
28 1 0 10 1 0 11 8 0 1 0 0 13 0
29 2 0 7 1 1 11 13 1 0 1 1 25 0 67 1
30 1 0 6 1 0 0 0 0 0 0 0 10 0
31 1 0 10 1 3 32 10 1 0 1 1 18 2 2 3
32 2 0 7 1 1 13 12 0 0 0 0 25 0
33 1 0 1 1 1 13 13 1 0 1 0 18 0
34 2 0 2 1 1 15 31 0 0 0 0 19 0
35 1 0 2 1 0 19 47 0 0 0 0 29 0
36 5 0 2 1 2 17 32 0 0 0 0 24 0
37 2 0 2 1 0 17 40 0 0 0 0 22 0
38 4 0 6 1 0 12 13 0 0 0 0 22 0
39 6 0 1 1 1 17 25 0 1 0 1 35 0 283 3
Sno Bld grp Preg Cond Px Rx E_ANC E-Plts Ac GVHD Chr GVHD Liver Gut FU1 GVHD Gd Bx Gd FU2 GVHD
40 1 0 2 1 0 0 0 0 0 0 0 22 0
41 1 0 11 1 0 13 16 1 0 0 0 21 0 32 2
42 1 0 1 1 0 17 10 1 0 0 0 21 2 1 2
43 2 0 2 1 2 19 45 0 0 0 0 17 0
44 2 1 12 5 0 0 0 0 0 0 0 27 0
45 4 0 2 1 0 15 36 1 0 0 0 20 2 2 1
46 4 0 13 1 3 12 12 1 0 1 1 11 0
47 2 0 14 1 0 20 57 1 1 1 0 22 0
48 4 0 3 1 3 16 17 1 0 1 0 15 2 3 1
49 1 0 7 1 3 16 47 0 0 0 0 28 0
50 1 0 7 1 1 16 12 0 0 0 0 19 0
51 1 1 2 1 0 0 0 0 0 0 0 10 0
52 3 0 7 1 1 15 12 1 1 0 1 11 0
53 4 0 6 1 3 14 13 1 0 0 1 59 0 70 2
54 1 0 3 1 4 24 29 1 0 1 1 11 0
55 6 0 2 1 0 16 14 0 0 0 0 24 0
56 4 0 6 1 1 28 0 1 0 1 1 21 2 3 1
57 1 1 1 1 3 28 14 1 0 1 1 16 0
58 2 1 8 3 3 17 10 1 0 1 0 29 0
59 4 0 13 1 0 17 15 0 0 0 0 24 0
60 4 - 5 1 3 13 17 1 0 1 1 21 0
61 4 0 1 1 0 12 0 0 0 0 0 15 0
62 1 0 1 1 1 9 15 0 0 0 0 30 0
63 2 0 2 1 1 16 33 1 1 1 1 16 2 1 3
64 2 0 13 1 0 16 15 0 0 0 0 24 0
65 2 0 6 1 0 16 13 0 1 0 0 24 0 178 3
66 4 0 6 1 0 15 18 0 0 0 0 2 0
67 1 0 7 1 3 15 13 1 0 1 1 11 2 1 2
68 1 0 1 1 1 13 12 1 0 0 1 30 0
69 2 1 8 1 1 9 0 0 0 0 0 24 0
70 1 1 1 1 3 14 13 1 1 1 1 15 2 3 1 166 2
71 1 0 13 1 1 0 0 1 0 0 0 14 2 1
72 1 0 13 1 1 14 21 0 0 0 0 7 0
73 1 0 1 1 1 16 21 1 1 0 1 28 0   48 3
74 8 0 13 1 0 20 26 0 0 0 0 24 0
75 1 0 13 1 0 18 38 1 0 0 0 3 0 49 3
76 2 0 8 1 0 20 35 0 0 0 0 25 0
77 4 1 6 1 0 13 13 0 0 0 0 21 0
78 1 0 2 1 0 20 0 0 0 0 0 24 0
Sno Bld grp Preg Cond Px Rx E_ANC E-Plts Ac GVHD Chr GVHD Liver Gut FU1 GVHD Gd Bx Gd FU2 GVHD
79 1 0 2 1 0 19 28 0 0 0 0 21 0
80 2 0 15 2 1 13 12 1 0 0 1 8 0
81 2 1 6 1 0 14 17 0 0 0 0 31 0
82 1 0 1 1 3 17 24 1 0 1 1 28 0
83 1 0 7 1 0 14 18 0 0 0 0 21 0
84 1 0 7 1 1 15 31 1 0 0 1 24 0
85 2 1 6 1 0 18 19 0 0 0 0 24 0
86 4 1 7 1 1 14 18 1 0 1 0 18 0
87 2 0 10 1 0 20 10 0 0 0 0 17 0
88 1 0 2 2 0 25 0 1 0 1 1 21 0
89 1 0 7 1 1 14 11 1 0 1 0 18 0
90 6 0 13 1 3 18 19 1 0 1 0 21 0 35 2
91 3 0 1 1 0 16 61 0 0 0 0 26 0
92 2 1 1 1 1 15 19 1 0 1 0 25 0 46 1
93 1 0 6 1 3 16 28 1 0 0 1 19 0
94 2 1 16 4 3 12 19 1 0 1 1 19 0 34 3
95 2 0 7 1 3 13 17 1 0 0 0 9 0 32 3
96 1 1 6 1 1 12 20 1 0 0 1 26 0
97 4 0 17 1 0 19 0 0 0 0 0 11 0
98 1 0 13 1 0 57 36 0 0 0 0 19 0
99 2 - 7 1 3 17 16 1 0 0 0 5 0 26 3
100 3 0 6 1 0 14 19 0 0 0 0 21 0
101 1 0 18 1 0 17 22 0 0 0 0 14 0
102 1 0 7 1 5 19 14 1 0 1 1 18 2 1 2 20 2
      
Sno Gd Bx Gd FU3 GVHD Gd Bx Gd FU4 GVHD Gd Bx Gd Relap Exp
1 497 3 1 2
2 505 0
3 170 1 515 0
4 81 0 1
5 2 140 1 3 492 2 1
6 91 0 1 1
7 462 0
8 1 3 312 0
9 87 0 1
10 13 0 1
11 322 3 1 2
12 456 0
13 100 0 1
14  451 0
15 437 0
16 436 0
17 402 3 1 2
18 377 2 1 2 419 2 1
19 432 3 1 2
20 397 0
21 8 0 1
22 65 0 1
23 9 0 1
24 379 0
25 336 0 1
26 8 0 1
27 370 0
28 376 1
29  2 291 1 387 0  1
30 12 0 1
31 78 3 1 3 217 1
32 373 0 1
33 157 0 1
34 45 0 1
35 352 0
36 348 0
37 346 0
38 295 0
39 1 322 1  341 0
Sno Gd Bx Gd FU3 GVHD Gd Bx Gd FU4 GVHD Gd Bx Gd Relap Exp
40 33 0 1
41 1 3 136 0 1
42 287 0
43 80 0 1 1
44 46 0 1
45 285 0
46 296 0
47 285 2 2 Chronic Lichenoid
48 34 2 3 3 241 0
49 242 0
50 25 0
51 15 0 1
52 231 3 1 289 3 1
53 3 269 0
54 58 0 1
55 271 0  
56 257 0
57     107 3 1 2 1
58 47 0 1
59 66 0
60 43 0 1
61 18 0 1
62 249 0
63 210 0
64 217 0
65 1 2 199 3 1 236 3 1
66 233 0
67 233 0
68 228 0
69 53 0 1
70 1 194 2 3 3 220 2 3
71 46 0 1
72 161 0
73 1 3 130 2 3 1 191 0  
74 138 0
75 1 2 49 3 1 2 154 0
76 191 0
77 182 0
78 33 0 1
Sno Gd Bx Gd FU3 GVHD Gd Bx Gd FU4 GVHD Gd Bx Gd Relap Exp
79 159 0
80 33 0
81 169 0
82 166 0
83 170 0 1
84 162 0
85 122 0
86 60 3 1 2 137 1
87 141 0
88 33 0 1
89 95 3 1 2 142 3 1
90 3 1 77 3 3 105 3 3
91 136 0 1
92 1 2 135 3 1
93 122 0
94 3 3 78 0 1
95 2 2 46 3 1 121 0
96 113 0
97 92 0
98 89 0  
99 3 3 46 3 3 107 2 3 2
100 96 0
101 82 0
102 4 93 0
 
